WO2013066835A2 - Compounds and methods - Google Patents

Compounds and methods Download PDF

Info

Publication number
WO2013066835A2
WO2013066835A2 PCT/US2012/062510 US2012062510W WO2013066835A2 WO 2013066835 A2 WO2013066835 A2 WO 2013066835A2 US 2012062510 W US2012062510 W US 2012062510W WO 2013066835 A2 WO2013066835 A2 WO 2013066835A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
oxadiazol
trifluoromethyl
carbamate
compound
Prior art date
Application number
PCT/US2012/062510
Other languages
French (fr)
Other versions
WO2013066835A3 (en
Inventor
Shomir Ghosh
Mercedes Lobera
Ryan Paul Trump
Cunyu Zhang
Peiling CHEN
Original Assignee
Glaxosmithkline Llc
Tempero Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc, Tempero Pharmaceuticals, Inc. filed Critical Glaxosmithkline Llc
Publication of WO2013066835A2 publication Critical patent/WO2013066835A2/en
Publication of WO2013066835A3 publication Critical patent/WO2013066835A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to compounds that inhibit histone deacetylase
  • HDAC HDAC enzymes
  • preparation of these compounds the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity and pharmaceutical compositions comprising these compounds.
  • Chromatin organization involves DNA wound around histone octamers that form nucleosomes.
  • Core histones with N-terminal tails extending from compact nucleosomal core particles can be acetylated or deacetylated at epsilon lysine residues affecting histone-DNA and histone-non-histone protein interactions.
  • Histone deacetylases HDACs catalyze the deacetylation of histone and non-histone proteins and play an important role in epigenetic regulation.
  • HDAC1 HDAC1 , HDAC2, HDAC3, HDAC8 and HDAC1 1
  • HDAC4 HDAC5
  • HDAC6, HDAC7, HDAC9 and HDAC10 which shuttle between the nucleus and the cytoplasm
  • SIRT1-7 class III HDACs
  • Class II HDACs are further characterized as class lla HDACs and class lib HDACs.
  • HDAC9 is a class lla histone deacetylase highly expressed in human Tregs.
  • HDAC9 deficiency 1 ) increases Foxp3 expression (and other Treg markers), 2) increases Foxp3 and histone 3 acetylation, 3) increases Foxp3 DNA binding, 4) increases Treg numbers, 5) increases suppressive activity in vitro and in vivo, and 6) ameliorates murine colitis.
  • Tregs which are deficient in HDAC9 induce permanent tolerance of fully mismatched cardiac allografts.
  • HDAC9 inhibitors maybe useful for treatment of diseases and disorders associated with abnormal cell proliferation, differentiation and survival, e.g. breast and prostate tumors.
  • HDAC7 a class lla histone deacetylase
  • HDAC7 enhances Treg suppression in vitro and in vivo.
  • HDAC7 enhances FOXP3+ Treg function and induces long-term allograft survival.
  • HDAC6 inhibition in vivo decreased severity of colitis in the dextran sodium sulphate-induced colitis model and the
  • CD4 + CD62Lhigh adoptive transfer model of colitis In addition, inhibition of HDAC6 with a subtherapeutic dose of rapamycin led to prolonged cardiac allograft survival.
  • an orally available small molecule selective inhibitor of Class II HDAC activity (more specifically HDAC9 or HDAC7 or HDAC6) is expected to modulate autoimmune diseases through expansion and enhancement of Treg activity.
  • HDAC4 and 5 impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes and maybe potentially useful for the treatment of muscle and heart diseases including cardiac hypertrophy and heart failure. Also, inhibition of Class II HDAC activity, represents a novel approach for disrupting or intervening in cell cycle regulation.
  • HDAC9 is also highly expressed in human B cells. Relative to normal B cells, expression of HDAC9 is deregulated in cell lines derived from B cell tumours and HDAC9 is highly overexpressed in cells derived from patients with non-Hodgkin's lymphoma (http://icr.ac.uk/research/team leaders/Zelent Arthur/Zelent Arthur Rl/index.shtml).
  • HDAC4 and HDAC9 have booth been reported to be overexpressed in CD 19+ cells from patients with Waldenstrom Macroglobulinemia (Sun et al., Clinical Lymphoma, Myeloma & Leukemia, 201 1 , p. 152)
  • Class Ma HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) have been reported to associate with Bcl-6, a transcription factor implicated in the pathogenesis of B-cell malignancies (Lemercier et al, Journal of Biological Chemistry, 2002, p. 22045, and Petrie et al, Journal of Biological Chemistry, 2003, p. 16059). Due to these interactions class lla HDACs have been suggested to modulate the transcriptional repression of BCL6 and participate in its role in B-cell activation and differentiation, inflammation, and cell-cycle regulation (Verdin et al. TRENDS in Genetics, 2003, p. 286) .
  • HDAC6 a class lib HDAC, has been reported to play an important role in aggresomal protein degradation, making it a target for the treatment of B cell
  • HDAC4 a small molecule selective inhibitor of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 and/or HDAC9 is expected to be beneficial in the treatment of B-cell malignancies by targeting one or several of the above enzymes
  • HDAC4 has been linked to a variety of neurodegenerative disorders: it is a downstream target of Parkin (associating it to Parkinson's disease); it is a major component of intranuclear inclusions produced in NIIND. HDAC4 also contains a conserved glutamine rich domain, such domain has been observed to increase susceptibility to amyloid formation associated with Alzheimer's disease (Majdzadeh et al. Front. Biosci., 2009, p. 1072). Heterozygotes of HDAC4 knockouts crossed to R6/2 mice (Huntington's disease model) led to improved motor/behavior and reduced aggregation
  • HDAC4 and HDAC5 localization are regulated by neuronal activity, and HDAC5 nuclear import is increased in diseased neurons of Huntington's disease patients.
  • HDAC7 has been implicated in regulating ataxin-7 turnover in a SCA-7 model (Mookerjee S et al., J Neurosci., 2009, p. 15134).
  • HDAC6 is expressed in most neurons and most abundantly in cerebellar Purkinje cells; the degeneration of this type of neurons is observed in patients with spinocerebellar ataxia type 1 (SCA1 ) or SCA7. HDAC6 is involved in regulating microtubule dynamics and protein degradation and a defect in microtubule-based transport may contribute to the neuronal toxicity observed in Huntington's disease (Kazantsev et al. Nature Reviews Drug Discovery, 2008, p. 854). Additionally, HDAC6 activity has been shown to be required for autophagic degradation of aggregated huntingtin, suggesting a role in protecting cells from polyQ toxicity (Iwata, et al., J. Biol. Chem., 2005, p. 40282).
  • HDAC4 or HDAC5 or HDAC6 or HDAC7or HDAC9 is expected to be beneficial in the treatment of neurodegenerative diseases.
  • Class II HDAC inhibitors have therapeutic potential in the study and/or treatment of the various diseases or conditions described herein.
  • HDAC inhibitors Many of the known small-molecule HDAC inhibitors, however, inhibit all HDAC isoforms. It would be advantageous to identify HDAC inhibitors that inhibited one or more, but not all HDAC isoforms.
  • the invention is directed to a compound according to Formula (I):
  • A is aryl (arylene), 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl (heteroarylene), or C 3 -i 4 cycloalkyl (cylcloalkylene) wherein said aryl, heteroaryl, or cycloalkyi, is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, haloC 1-4 alkyl, haloC 1-4 alkyloxy, C 1-4 alkyl-carbonyl-, C 1-4 alkoxy-carbonyl-, C 1-4 alkyl-carbonylamino-; m is 0, 1 , 2, 3, or 4;
  • F is CONH, NHCO, NHCOO or NHCONR 2 , where R 2 is hydrogen or C 1-4 alkyl; n is 0, 1 , 2, 3, or 4;
  • Y is a bond, O, S, NR 3 , C(O), NR 4 C(0), or C(0)NR 4 , wherein R 3 is H, C ⁇ alkyl, or -COR 3a , wherein R 3a is phenyl, or heterocyclyl, and R 4 is H or Ci -4 alkyl;
  • Y is selected from the group consisting of a bond, C(O), and C(0)NR 4 ;
  • p 0, 1 , 2, 3, or 4;
  • R 1 is H, phenyl or 5-6 membered heteroaryl, wherein said phenyl or heteroaryl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, Cr 4 alkyl, haloCr 4 alkyl, Ci- 4 alkoxy, haloCr 4 alkoxy, -NR 5 R 5 and -(C 4 alkyl)NR 5 R 5 ;
  • B is aryl, 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, C 3-14 cycloalkyl, adamantyl, or 5-6 membered heterocyclyl, wherein said aryl, heteroaryl, C 3-14 cycloalkyl, adamantyl, or heterocyclyl is optionally substituted by 1 -4 substituents each independently selected from the group consisting of halogen, nitro, cyano, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkyl, haloC 1-4 alkoxy, C 1-4 alkyl-carbonyl-,
  • r 1 or 2
  • said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, Ci -4 alkyl, haloCi -4 alkyl, C ⁇ alkoxy, haloCi -4 alkoxy, -NR 6 R 6 , and -C ⁇ alkylNR ⁇ 6 ,
  • each R 5 is independently selected from the group consisting of H and Cr 4 alkyl
  • each R 6 is independently selected from the group consisting of H, d ⁇ alkyl, Ci -4 alkyl-carbonyl-, and
  • compositions comprising compounds of the invention and a pharmaceutical carrier are also provided.
  • the invention is further directed to a method of treating a subject having a disease or disorder mediated by inhibition of a HDAC comprising administering the compound of Formula I, or a salt thereof, or a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, to the subject.
  • alkyl represents a saturated, straight, or branched hydrocarbon moiety.
  • exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, / ' so-pentyl (3-methyl- butyl), neo-pentyl (2,2-dimethylpropyl), etc.
  • alkyl When the term “alkyl” is used in combination with other substituent groups, such as “haloalkyl” or “cycloalkyl-alkyl” or “arylalkyl”, the term “alkyl” is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
  • arylalkyl is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH 2 -phenyl).
  • cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring.
  • (C 3 -C 8 )cycloalkyl refers to a non-aromatic cyclic
  • hydrocarbon ring having from three to eight ring carbon atoms.
  • C 3 - 8 cycloalkyl groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Alkoxy refers to a group containing an alkyl radical attached through an oxygen linking atom.
  • C 4 alkoxy refers to a straight- or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
  • Exemplary "Ci- 4 alkoxy” groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
  • Aryl represents a group or moiety comprising an aromatic, monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms and to which may be fused one or more cycloalkyl rings.
  • Heterocyclyl represents a group or moiety comprising a stable, non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocyclyl may be attached by any atom of the monocyclic or bicyclic radical which results in the creation of a stable structure.
  • This term encompasses bicyclic heterocyclyl moieties where the rings are joined at two atoms per ring, as exemplified by the bonding arrangement in 2,5-diazabicyclo[2.2.1]heptyl, 2- azabicyclo[2.2.1 ]heptyl, 2-oxa-5-azabicyclo[2.2.1 ]heptyl, 7-oxa-2-azabicyclo[2.2.1 ]heptyl, 2-thia-5-azabicyclo[2.2.1]heptyl,7-azabicyclo[2.2.1 ]heptyl, 2,6- diazatricyclo[3.3.1 .13,7]decyl, 2-azatricyclo[3.3.1.13,7]decyl, 2,4,9- triazatricyclo[3.3.1.13,7]decyl, 8-azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2- azabicyclo[2.2.2
  • This term specifically excludes bicyclic heterocyclyl moieties where the rings are joined at a single atom per ring (spiro), as exemplified by the bonding arrangement in a 1 -oxa-2-azaspiro[4.5]dec-2-en-3-yl group.
  • heterocyclyls include, but are not limited to, azetidinyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3- dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.
  • heterocyclyl groups are
  • 5-membered and/or 6-membered heterocyclyl groups such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuranyl, tetrahydrothienyl, dihydrofuranyl, oxazolinyl, thiazolinyl or pyrazolinyl, piperidyl (or piperidinyl), piperazinyl, morpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3- dioxanyl, tetrahydro-2H-1 ,4-thiazinyl, 1 ,4-dioxanyl, 1 ,3-oxathianyl, and 1 ,3-dithianyl.
  • pyrrolidyl or pyrrolidinyl
  • tetrahydrofuranyl tetrahydrothienyl
  • dihydrofuranyl oxazolinyl
  • Heteroaryl represents a group or moiety comprising an aromatic monocyclic, bicyclic, or tricyclic radical, containing 5 to 14 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term also encompasses bicyclic or tricyclic heterocyclic-aryl compounds containing one or two aryl ring moieties fused to a heterocyclyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur where the nitrogen or sulfur heteroatoms are optionally oxidized.
  • heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridinyl, pyridyl-N- oxide, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[b]thienyl, isobenzofuranyl, 2,3-dihydrobenzofuranyl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl,
  • heteroaryl groups present in the compounds of this invention are 5-6 membered monocyclic heteroaryl groups.
  • Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
  • Selected 6-membered heteroaryl groups contain 1 , 2, 3 or 4 nitrogen ring heteroatoms.
  • Selected 5- or 6-membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and thiadiazolyl.
  • heteroaryl groups present in the compounds of this invention are 9-10 membered bicyclic heteroaryl groups.
  • Selected 9-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
  • Selected 10-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms.
  • Selected 9-10 membered heteroaryl groups include benzo[b]thienyl, isobenzofuranyl, 2,3-dihydrobenzofuranyl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl.
  • alkyl, aryl, cycloalkyl, heteroaryl, etc. may be used to define a divalent substituent, such as a group bonded to two other groups. In this instance, such terms are intended to encompass divalent moieties.
  • pentyl may be used to represent a pentylenyl diradical -wherein the pentyl moiety is any one of a divalent straight (e.g. -CH 2 CH 2 CH 2 CH 2 CH 2 -) or branched (e.g. -CH 2 CH(CH 3 )CH 2 CH 2 -,
  • A is phenyl (phenylene), 6-membered, monocyclic or 9-10 membered, bicyclic heteroaryl (heteroarylene), or C 5 - 7 cylcloalkyl (cycloalkylene), wherein said phenyl, heteroaryl, or cycloalkyl is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen,
  • A is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5- a]pyridinyl, or quinolyl, wherein said phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5- a]pyridinyl, or quinolyl is optionally substituted 1 -2 substituents each independently selected from the group consisting of Ci -4 alkyl, C
  • A is unsubstituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinzolinyl.
  • n is 0 or m is 1 . In another embodiment, m is 2. In a further embodiment, m is 3 or 4.
  • n is 0, 1 , 2, or 3. In one specific embodiment, n is 0. In another specific embodiment, n is 1 . In a further specific embodiment, n is 2.
  • Y is a bond, O, NR 3 , C(O), NR 4 C(0), or C(0)NR 4 , wherein R 3 is H, Ci -2 alkyl, or -COR 3a , wherein R 3a is Ci -3 alkyl, haloCi -2 alkyl, phenyl, or heterocyclyl, and R 4 is H or C 1-2 alkyl.
  • Y is a bond.
  • Y is C(O) or C(0)NR 4 , wherein R 4 is H or C 1-2 alkyl.
  • p is 0. In a further embodiment, p is 1 or 2 and R 1 is H or phenyl. In yet another embodiment, p is 2, 3, or 4. In selected embodiments, p is 0.
  • B is phenyl, naphthyl, 6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, or C 5 - 7 cycloalkyl, wherein said phenyl, naphthyl, heteroaryl, or cycloalkyi is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, hydroxy, Ci -3 alkyl, Ci -3 alkoxy, haloCi -2 alkyl, haloCi -2 alkoxy, Ci -3 alkyl-carbonyl-, Ci -3 alkoxy-carbonyl-,
  • said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, cyano, Ci_ 3 alkyl, haloCi -2 alkyl, Ci -3 alkoxy, haloCi -2 alkoxy, -NR 6 R 6 , and -C ⁇ alkylNR ⁇ 6 ,
  • each R 5 is independently selected from the group consisting of H and Ci -2 alkyl
  • each R 6 is independently selected from the group consisting of H, Ci -2 alkyl,
  • B is phenyl or pyridinyl, optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, -C(0)NH 2 , -S0 2 NH 2 , -C(0)OCH 3 , phenyl, pyridinyl, pyrrolidinyl, piperidinyl, morpholinyl, or -NR Ba R Ba , -C 1-4 alkylNR 6 R 6 , wherein each R 6 is independently selected from the group consisting of H, Ci -2 alkyl, and -C(0)CH 3 .
  • B is naphthyl, quinolyl, isoquinolyl, furo[3,2-c]pyridinyl, or 5,6,7, 8-tetrahydroquinolyl.
  • the invention provides a compound of Formula (la):
  • X is a bond, O or NR 2 , where R 2 is H or
  • R 2 is hydrogen; and A, m, n and B are as defined herein.
  • S, T, V, and U are each independently selected from the group consisting of N or CH.
  • two of S, T, V, and U are N and two are CH.
  • one of S, T, V, and U is N and three are CH.
  • the terms "compound(s) of the invention” or “compound(s) of this invention” mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a
  • any physical form thereof e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
  • non-solid forms e.g., liquid or semi-solid forms
  • solid forms e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)
  • mixtures of various forms e.g., including hydrate forms (e.g., mono-, di- and hemi- hydrates)
  • optionally substituted means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and groups or rings substituted with one or more specified substituents.
  • the compounds according to Formula (I) may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
  • Chiral centers such as chiral carbon atoms, may also be present in a substituent such as an alkyl group.
  • the stereochemistry of a chiral center present in Formula (I), or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
  • compounds according to Formula (I) containing one or more chiral centers may be used as racemic mixtures, scalemic mixtures, or as diaseteromerically or enantiomerically pure materials.
  • diastereoisomeric salts, complexes or other derivatives (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • a stereoisomer-specific reagent for example by enzymatic oxidation or reduction
  • gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • polymorphism i.e. the capacity to occur in different crystalline forms. These different crystalline forms are typically known as "polymorphs.” It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
  • Formula (I) are preferably pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse,
  • salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention.
  • a salt may be readily prepared by using a desired acid or base as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as
  • Suitable addition salts are formed from acids which form non-toxic salts and examples include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxyn
  • exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, ⁇ -hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene-1 -sulfonate and naphthalene-2-sulfonate.
  • an inventive basic compound is isolated as a salt
  • the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pK a than the free base form of the compound.
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • an inorganic or organic base such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia such as glycine and arginine
  • primary, secondary, and tertiary amines such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine
  • Certain of the compounds of this invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety).
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
  • Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
  • This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention, e.g., a hydrochloride salt, into another
  • a pharmaceutically acceptable salt of a compound of this invention e.g., a sulfate salt.
  • solvates of the compounds of Formula (I), or salts thereof that are in crystalline form may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization.
  • Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as
  • Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.
  • the invention includes all such solvates.
  • the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
  • the compounds of this invention may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist.
  • the synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different substituent groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed.
  • the Schemes are shown with compounds only of Formula (I), they are illustrative of processes that may be used to make the compounds of the invention.
  • Intermediates (compounds used in the preparation of the compounds of the invention) may also be present as salts.
  • the phrase "compound(s) of formula (number)" means a compound having that structural formula or a pharmaceutically acceptable salt thereof.
  • Specific compounds of this invention are the compounds of Examples 1 -1 1 including salts, particularly pharmaceutically acceptable salts, thereof.
  • quinolin-3-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate; isoquinolin-4-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate; furo[3,2-c]pyridin-7-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
  • quinolin-3-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
  • quinolin-3-ylmethyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
  • quinolin-3-ylmethyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
  • quinolin-3-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
  • quinolin-3-ylmethyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
  • quinolin-3-ylmethyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
  • quinolin-3-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3-yl)carbamate; isoquinolin-4-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
  • quinolin-3-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5-yl)carbamate; isoquinolin-4-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
  • quinolin-3-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5-a]pyridin-4- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
  • quinolin-3-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)carbamate; isoquinolin-4-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)carbamate; furo[3,2-c]pyridin-7-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
  • quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2-yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
  • quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2-yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
  • quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
  • furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
  • ChemDraw 1 1.0 available from CambridgeSoft Corporation, 100 CambridgePark Drive, Cambridge, MA 02140, USA (http://www.cambridgesoft.com).
  • the compounds of Formula (I) can be prepared according to the methods outlined below.
  • the invention also includes various deuterated forms of the compounds of
  • Each available hydrogen atom attached to a carbon atom may be any available hydrogen atom attached to a carbon atom.
  • deuterated alkyl groups e.g., /V-(deutero-methyl) amines
  • deuterated alkyl groups may be prepared by conventional techniques (see for example: methyl-c/3-amine available from Aldrich Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2).
  • Employing such compounds will allow for the preparation of compounds of Formula (I) in which various hydrogen atoms of the /V-methyl groups are replaced with a deuterium atom.
  • the present invention is directed to a method of inhibiting an HDAC which comprises contacting the acetylase with a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. More specifically, this invention is directed to a method of inhibiting HDAC comprising contacting a cell with an effective amount of a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of an HDAC-mediated disease or disorder comprising administering a therapeutically effective amount of the compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • patient refers to a mammal, specifically, a human.
  • a therapeutically "effective amount” is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
  • a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to inhibit the activity of HDAC such that a disease condition which is mediated by that activity is reduced, alleviated or prevented.
  • the amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC 50 ), efficacy (EC 50 ), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can
  • Treating is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by HDAC.
  • the methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
  • this invention is directed to a method of treating, ameliorating, or preventing an autoimmune disorder, an immunological disease, an inflammatory disorder, transplant/graft rejection (e.g., allograft), lymphopenia, or graft-versus-host disease (GvHD) in a patient, specifically in a human, comprising administering to the patient a compound of this invention, in an amount sufficient to increase the level and/or activity of a Treg cell or a population of Treg cells in the patient, thereby treating, ameliorating, or preventing the autoimmune disorder, inflammatory disorder,
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., allograft
  • GvHD graft-versus-host disease
  • transplant/graft rejection transplant/graft rejection, lymphopenia, or GvHD in the patient.
  • diseases and conditions that may be treated by the compounds of this invention include but not limited to type II diabetes mellitus, coronary artery disease, alopecia, allergies and allergic reactions, and sepsis/toxic shock.
  • Exemplary autoimmune disorders include, but are not limited to, multiple sclerosis, juvenile idiopathic arthritis, psoriatic arthritis, hepatitis C virus-associated mixed cryoglobulinemia, polymyositis, dermatomyositis, polyglandular syndrome type II, autoimmune liver disease, Kawasaki disease, myasthenia gravis, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX (syndrome)), type I diabetes, psoriasis, hypothyroidism, hemolytic anemia, autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED), thrombocytopenia, spondyloarthritis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, eczema, gastritis, or thyroiditis.
  • the inflammatory bowel disease IBD
  • autoimmune diseases include osteoarthritis, systemic sclerosis, sarcoidosis, insulin dependent diabetes mellitus (IDDM, type I diabetes), reactive arthritis, scleroderma, vasculitis, Wegener's granulomatosis, Hashimoto's disease, scleroderma, oophoritis, Lupus (SLE), Grave's disease, asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
  • IDDM insulin dependent diabetes mellitus
  • SLE oophoritis
  • Grave's disease asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • graft- versus-host disease e.g., graft- versus-host disease
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • graft- versus-host disease e.g., graft- versus-host disease
  • transplant/graft rejection e.g., allograft
  • lymphopenia e.g., lymphopenia
  • GvHD graft- versus-host disease
  • this invention is directed to a method of treating an HDAC-mediated neurodegenerative disease or disorder which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • This invention is also directed to a method of treatment of a neurodegenerative disease or disorder associated with deacetylases, such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • deacetylases such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA)
  • diseases and conditions include but are not limited to cystic fibrosis, osteoporosis, obesity, epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia, cardiac disease (e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation of infarct size in acute coronary syndrome), diseases or disorders involving muscular atrophy, gentamicin-induced hearing loss, drug resistance (e.g., drug resistance in osteosarcoma and colon cancer cells), infectious diseases, and immune deficiency/immunocompromised patients.
  • cystic fibrosis e.g., osteoporosis
  • obesity e.g., epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia
  • cardiac disease e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation
  • infectious diseases relate to various pathogen infections such as viral, fungal, bacterial, mycoplasm, and infections by unicellular and multicellular eukaryotic organisms.
  • pathogens include but are not limited to HIV, HSV, HPV, Hepatitis A, B and C viruses, influenza, denge, zostrella, rubella, RSV, rotavirus, gram positive, gram negative, streptococcus, tetanus, staphalococcus, tuberculosis, listeria, and malaria.
  • the compounds of the invention may be employed alone or in combination with standard anti-cancer regimens for neoplastic cell, e.g., tumor cell and cancer cell, treatments.
  • this invention is directed to inhibitors of HDAC and their use to stop or reduce the growth of neoplastic cells, e.g., cancer cells and tumor cells.
  • carcinoma e.g., adenocarcinoma
  • heptaocellular carcinoma e.g., sarcoma
  • myeloma e.g., multiple myeloma
  • treating bone disease in multiple myeloma leukemia, childhood acute lymphoblastic leukemia and lymphoma (e.g., cutaneous cell lymphoma)
  • mixed types of cancers such as adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, and teratocarcinoma.
  • breast or prostate cancers or tumors are treated using the HDAC inhibitors of this invention.
  • Other cancers that may be treated using the compounds of this invention include, but are not limited to, bladder cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, endometrial cancer, pancreatic cancer, cervical cancer, ovarian cancer; head and neck cancer, and melanoma.
  • the present invention is further directed to a method of treating a B-cell lymphoma, particularly a B-cell lymphoma associated with deacetylases, which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • B-cell lymphomas associated with deacetylases include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and
  • this invention is directed to a method of treatment of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
  • CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma
  • follicular lymphoma immunoblastic large cell lymphoma
  • precursor B-lymphoblastic lymphoma precursor B-lymphoblastic lymphoma
  • mantle cell lymphoma mantle cell lymphoma
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
  • Parenteral administration refers to routes of administration other than enteral
  • transdermal, or by inhalation and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • Treatment of HDAC-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other agents, for example, in combination with one or more of the following agents: DNA methyltransferase inhibitors, acetyl transferase enhancers, proteasome or HSP90 inhibitors, and one or more immunosuppressants that do not activate the T suppressor cells including but are not limited to corticosteroids, rapamycin, Azathioprine, Mycophenolate, Cyclosporine, Mercaptopurine (6-MP), basiliximab, daclizumab, sirolimus, tacrolimus, Muromonab-CD3, cyclophosphamide, and
  • methotrexate which are administered in effective amounts as is known in the art.
  • the compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form.
  • a dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula (I) or a salt, particularly a pharmaceutically acceptable salt, thereof).
  • the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
  • pharmaceutically-acceptable excipient means a material, composition or vehicle involved in giving form or consistency to the composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
  • the compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
  • Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants,
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • 2-(4-(5-(Trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetic acid A solution of 2-(4- cyanophenyl)acetic acid (2 g, 12.41 mmol) and hydroxylamine (50% in H 2 0) (1.901 ml_, 31 .0 mmol) was refluxed in ethanol (40 ml.) overnight. The reaction was concentrated under reduced pressure and dried overnight in a vacuum oven. The resulting white solid was taken up in THF (40 ml_), and Et 3 N (3.87 ml_, 27.8 mmol) and TFAA (3.87 ml_, 27.8 mmol) were added at 0 °C.
  • a -Phenyl-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide Aniline (0.018 ml_, 0.202 mmol), HATU (77 mg, 0.202 mmol) and / ' -Pr 2 NEt (0.096 ml_, 0.551 mmol) were added to a solution of 2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetic acid (50 mg, 0.184 mmol) in DMF (1 ml.) . The reaction was stirred at rt for 2 h.
  • Pyridin-3-ylmethyl 4-cyanobenzylcarbamate Pyridin-3-ylmethanol (0.546 g, 5 mmol) in THF (2ml) was added to a suspension of 1 , 1 '-carbonyldiimidazole (0.81 1 g, 5.00 mmol) in THF (8ml) at 10 °C. The mixture was stirred for 1 h at rt. The resultant solution was added to the solution of 4-(aminomethyl)benzonitrile (0.661 g, 5.00 mmol), DBU (0.754 ml_, 5.00 mmol), and Et 3 N (0.697 ml_, 5.00 mmol) in THF (10 ml).
  • Tablets are prepared using conventional methods and are formulated as follows:
  • Capsules are prepared using conventional methods and are formulated as follows:
  • HDAC9 Histone Deacetylase 9
  • Novel histone deacetylase 9 (HDAC9) inhibitors were characterized in an in vitro biochemical functional assay.
  • the assay measures the increased fluorescent signal due to deacetylation, by HDAC9, of a fluorogenic substrate.
  • the commercial available substrate is Class lla HDAC-specific and contains an acetylated lysine residue and would releases the fluorescent signal upon trypsin cleavage after deacetylation.
  • test compounds diluted to various concentrations in 100% DMSO are first dispensed into 384-well assay plates.
  • Recombinant HDAC9 isoform 4 (purchased from BPS Bioscience) in complete assay buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1 mM MgCI 2 , 0.05% BSA & 0.005% Tween 20) were then added to each well (5uL/well) using Multidrop Combi (Thermo Scientific), followed by 5 uL/well substrate (purchased from BPS Bioscience, 4.5 uM final).
  • plC50s For concentration/dose response experiments, normalized data were fit and plC50s determined using conventional techniques. The plC 50 s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compound of Examples 1 -1 1 exhibited a plC 50 between 5.0 and 9.0 e.g., for example, the compound of Examples 1 , 2, 3 and 4 inhibited HDAC9 in the above method with a mean plC50 > 6.
  • HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival L. Wang, et al., Am. J. Transplant 9, S621 (2009).
  • HDAC-MEF2 complexes A. Nebbioso, F. Manzo, M. Miceli, M. Conte, L. Manente, A. Baldi, A. De Luca, D. Rotili, S. Valente, A. Mai, A. Usiello, H.
  • Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender- Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor
  • E. van Rooij J. Fielitz, L. B. Sutherland, V. L. Thijssen, H. J. Crijns, M. J. Dimaio, J. Shelton, L. J. De Windt, J. A. Hill, E.N. Olson, Circulation Research, Jan 2010.

Abstract

Disclosed are compounds having the formula (I), wherein A, n, X, o, Y, R1, p, and B are as defined herein, and methods of making and using the same.

Description

COMPOUNDS AND METHODS
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds that inhibit histone deacetylase
(HDAC) enzymes, the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity and pharmaceutical compositions comprising these compounds. Background of the Invention
Chromatin organization involves DNA wound around histone octamers that form nucleosomes. Core histones with N-terminal tails extending from compact nucleosomal core particles can be acetylated or deacetylated at epsilon lysine residues affecting histone-DNA and histone-non-histone protein interactions. Histone deacetylases (HDACs) catalyze the deacetylation of histone and non-histone proteins and play an important role in epigenetic regulation. There are currently 18 known HDACs that are organized into three classes: class I HDACs (HDAC1 , HDAC2, HDAC3, HDAC8 and HDAC1 1 ) are mainly localized to the nucleus; class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10), which shuttle between the nucleus and the cytoplasm; and class III HDACs (SIRT1-7), whose cellular localization includes various organelles.
Class II HDACs are further characterized as class lla HDACs and class lib HDACs.
HDAC9 is a class lla histone deacetylase highly expressed in human Tregs. HDAC9 deficiency: 1 ) increases Foxp3 expression (and other Treg markers), 2) increases Foxp3 and histone 3 acetylation, 3) increases Foxp3 DNA binding, 4) increases Treg numbers, 5) increases suppressive activity in vitro and in vivo, and 6) ameliorates murine colitis. Tregs which are deficient in HDAC9 induce permanent tolerance of fully mismatched cardiac allografts. In addition, HDAC9 inhibitors maybe useful for treatment of diseases and disorders associated with abnormal cell proliferation, differentiation and survival, e.g. breast and prostate tumors.
Preliminary data shows that targeting HDAC7, a class lla histone deacetylase, enhances Treg suppression in vitro and in vivo. HDAC7 enhances FOXP3+ Treg function and induces long-term allograft survival.
Inhibition of HDAC6, a class lib HDAC, has been shown to increase Treg suppressive function in vitro along with increased expression of FOXP3 protein and Treg associated genes including CTLA, IL-10, TNR18. HDAC6 inhibition in vivo decreased severity of colitis in the dextran sodium sulphate-induced colitis model and the
CD4+CD62Lhigh adoptive transfer model of colitis. In addition, inhibition of HDAC6 with a subtherapeutic dose of rapamycin led to prolonged cardiac allograft survival.
Thus, an orally available small molecule selective inhibitor of Class II HDAC activity (more specifically HDAC9 or HDAC7 or HDAC6) is expected to modulate autoimmune diseases through expansion and enhancement of Treg activity.
Inhibition of other Class II HDAC's for example HDAC4 and 5 impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes and maybe potentially useful for the treatment of muscle and heart diseases including cardiac hypertrophy and heart failure. Also, inhibition of Class II HDAC activity, represents a novel approach for disrupting or intervening in cell cycle regulation.
HDAC9 is also highly expressed in human B cells. Relative to normal B cells, expression of HDAC9 is deregulated in cell lines derived from B cell tumours and HDAC9 is highly overexpressed in cells derived from patients with non-Hodgkin's lymphoma (http://icr.ac.uk/research/team leaders/Zelent Arthur/Zelent Arthur Rl/index.shtml).
HDAC4 and HDAC9 have booth been reported to be overexpressed in CD 19+ cells from patients with Waldenstrom Macroglobulinemia (Sun et al., Clinical Lymphoma, Myeloma & Leukemia, 201 1 , p. 152)
Class Ma HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) have been reported to associate with Bcl-6, a transcription factor implicated in the pathogenesis of B-cell malignancies (Lemercier et al, Journal of Biological Chemistry, 2002, p. 22045, and Petrie et al, Journal of Biological Chemistry, 2003, p. 16059). Due to these interactions class lla HDACs have been suggested to modulate the transcriptional repression of BCL6 and participate in its role in B-cell activation and differentiation, inflammation, and cell-cycle regulation (Verdin et al. TRENDS in Genetics, 2003, p. 286) .
HDAC6, a class lib HDAC, has been reported to play an important role in aggresomal protein degradation, making it a target for the treatment of B cell
malignancies (Simms-Waldrip et al., Molecular Genetics and Metabolism, 2008, p. 283)
Accordingly, a small molecule selective inhibitor of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 and/or HDAC9 is expected to be beneficial in the treatment of B-cell malignancies by targeting one or several of the above enzymes
HDAC4, HDAC5 and HDAC9 are also highly expressed in the brain. HDAC4 has been linked to a variety of neurodegenerative disorders: it is a downstream target of Parkin (associating it to Parkinson's disease); it is a major component of intranuclear inclusions produced in NIIND. HDAC4 also contains a conserved glutamine rich domain, such domain has been observed to increase susceptibility to amyloid formation associated with Alzheimer's disease (Majdzadeh et al. Front. Biosci., 2009, p. 1072). Heterozygotes of HDAC4 knockouts crossed to R6/2 mice (Huntington's disease model) led to improved motor/behavior and reduced aggregation
(http://bmi.epfl.ch/files/content/sites/bmi/files/shared/Abstract Gillian Bates.pdD. HDAC4 and HDAC5 localization are regulated by neuronal activity, and HDAC5 nuclear import is increased in diseased neurons of Huntington's disease patients.
HDAC7 has been implicated in regulating ataxin-7 turnover in a SCA-7 model (Mookerjee S et al., J Neurosci., 2009, p. 15134).
HDAC6 is expressed in most neurons and most abundantly in cerebellar Purkinje cells; the degeneration of this type of neurons is observed in patients with spinocerebellar ataxia type 1 (SCA1 ) or SCA7. HDAC6 is involved in regulating microtubule dynamics and protein degradation and a defect in microtubule-based transport may contribute to the neuronal toxicity observed in Huntington's disease (Kazantsev et al. Nature Reviews Drug Discovery, 2008, p. 854). Additionally, HDAC6 activity has been shown to be required for autophagic degradation of aggregated huntingtin, suggesting a role in protecting cells from polyQ toxicity (Iwata, et al., J. Biol. Chem., 2005, p. 40282).
Accordingly, a small molecule selective inhibitor of HDAC activity (more
specifically HDAC4 or HDAC5 or HDAC6 or HDAC7or HDAC9) is expected to be beneficial in the treatment of neurodegenerative diseases.
Class II HDAC inhibitors have therapeutic potential in the study and/or treatment of the various diseases or conditions described herein.
Many of the known small-molecule HDAC inhibitors, however, inhibit all HDAC isoforms. It would be advantageous to identify HDAC inhibitors that inhibited one or more, but not all HDAC isoforms.
SUMMARY OF THE INVENTION
The invention is directed to a compound according to Formula (I):
Figure imgf000004_0001
wherein:
A is aryl (arylene), 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl (heteroarylene), or C3-i4cycloalkyl (cylcloalkylene) wherein said aryl, heteroaryl, or cycloalkyi, is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, haloC1-4alkyl, haloC1-4alkyloxy, C1-4alkyl-carbonyl-, C1-4alkoxy-carbonyl-, C1-4alkyl-carbonylamino-; m is 0, 1 , 2, 3, or 4;
F is CONH, NHCO, NHCOO or NHCONR2, where R2 is hydrogen or C1-4alkyl; n is 0, 1 , 2, 3, or 4;
Y is a bond, O, S, NR3, C(O), NR4C(0), or C(0)NR4, wherein R3 is H, C^alkyl, or -COR3a, wherein R3a is
Figure imgf000005_0001
phenyl, or heterocyclyl, and R4 is H or Ci-4alkyl;
wherein when n is 1 and F is CONH, NHCOO or NHCONR2, then Y is selected from the group consisting of a bond, C(O), and C(0)NR4;
p is 0, 1 , 2, 3, or 4;
R1 is H, phenyl or 5-6 membered heteroaryl, wherein said phenyl or heteroaryl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, Cr4alkyl, haloCr4alkyl, Ci-4alkoxy, haloCr4alkoxy, -NR5R5 and -(C 4alkyl)NR5R5;
B is aryl, 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, C3-14cycloalkyl, adamantyl, or 5-6 membered heterocyclyl, wherein said aryl, heteroaryl, C3-14cycloalkyl, adamantyl, or heterocyclyl is optionally substituted by 1 -4 substituents each independently selected from the group consisting of halogen, nitro, cyano, hydroxy, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy, C1-4alkyl-carbonyl-,
Ci-4alkoxy-carbonyl-,
Figure imgf000005_0002
C1-4alkylthio, -CONR5R5, -SOrNR5R5, -NR6R6, -Ci-4alkylNR6R6, phenyl, and 5-6 membered heterocyclyl,
wherein:
r is 1 or 2,
said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, Ci-4alkyl, haloCi-4alkyl, C^alkoxy, haloCi-4alkoxy, -NR6R6, and -C^alkylNR^6,
each R5 is independently selected from the group consisting of H and Cr4alkyl; and
each R6 is independently selected from the group consisting of H, d^alkyl, Ci-4alkyl-carbonyl-, and
Figure imgf000005_0003
or a salt thereof, particularly a pharmaceutically acceptable salt, thereof.
Pharmaceutical compositions comprising compounds of the invention and a pharmaceutical carrier are also provided. The invention is further directed to a method of treating a subject having a disease or disorder mediated by inhibition of a HDAC comprising administering the compound of Formula I, or a salt thereof, or a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, to the subject. DETAILED DESCRIPTION OF THE INVENTION
The alternative definitions for the various groups and substituent groups of Formula (I) provided throughout the specification are intended to particularly describe each compound species disclosed herein, individually, as well as groups of one or more compound species. The scope of this invention includes any combination of these group and substituent group definitions.
As used herein, the term "alkyl" represents a saturated, straight, or branched hydrocarbon moiety. Exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, /'so-pentyl (3-methyl- butyl), neo-pentyl (2,2-dimethylpropyl), etc. The term "Cr4" refers to an alkyl containing from 1 to 4 carbon atoms.
When the term "alkyl" is used in combination with other substituent groups, such as "haloalkyl" or "cycloalkyl-alkyl" or "arylalkyl", the term "alkyl" is intended to encompass a divalent straight or branched-chain hydrocarbon radical. For example, "arylalkyl" is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH2-phenyl).
As used herein, the term "cycloalkyl" refers to a non-aromatic, saturated, cyclic hydrocarbon ring. The term "(C3-C8)cycloalkyl" refers to a non-aromatic cyclic
hydrocarbon ring having from three to eight ring carbon atoms. Exemplary
"C3-8cycloalkyl" groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
"Alkoxy" refers to a group containing an alkyl radical attached through an oxygen linking atom. The term "C 4alkoxy" refers to a straight- or branched-chain hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom. Exemplary "Ci-4alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
"Aryl" represents a group or moiety comprising an aromatic, monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms and to which may be fused one or more cycloalkyl rings.
"Heterocyclyl" represents a group or moiety comprising a stable, non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. The heterocyclyl may be attached by any atom of the monocyclic or bicyclic radical which results in the creation of a stable structure. This term encompasses bicyclic heterocyclyl moieties where the rings are joined at two atoms per ring, as exemplified by the bonding arrangement in 2,5-diazabicyclo[2.2.1]heptyl, 2- azabicyclo[2.2.1 ]heptyl, 2-oxa-5-azabicyclo[2.2.1 ]heptyl, 7-oxa-2-azabicyclo[2.2.1 ]heptyl, 2-thia-5-azabicyclo[2.2.1]heptyl,7-azabicyclo[2.2.1 ]heptyl, 2,6- diazatricyclo[3.3.1 .13,7]decyl, 2-azatricyclo[3.3.1.13,7]decyl, 2,4,9- triazatricyclo[3.3.1.13,7]decyl, 8-azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2- azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1 ]octyl, 8-azabicyclo[3.2.1]octyl, octahydro-1 H- pyrrolo[3,2-6]pyridyl group. This term specifically excludes bicyclic heterocyclyl moieties where the rings are joined at a single atom per ring (spiro), as exemplified by the bonding arrangement in a 1 -oxa-2-azaspiro[4.5]dec-2-en-3-yl group. Illustrative examples of heterocyclyls include, but are not limited to, azetidinyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3- dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl and 1 ,5,9-triazacyclododecyl.
Generally, in the compounds of this invention, heterocyclyl groups are
5-membered and/or 6-membered heterocyclyl groups, such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuranyl, tetrahydrothienyl, dihydrofuranyl, oxazolinyl, thiazolinyl or pyrazolinyl, piperidyl (or piperidinyl), piperazinyl, morpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3- dioxanyl, tetrahydro-2H-1 ,4-thiazinyl, 1 ,4-dioxanyl, 1 ,3-oxathianyl, and 1 ,3-dithianyl.
"Heteroaryl" represents a group or moiety comprising an aromatic monocyclic, bicyclic, or tricyclic radical, containing 5 to 14 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term also encompasses bicyclic or tricyclic heterocyclic-aryl compounds containing one or two aryl ring moieties fused to a heterocyclyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. This term is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur where the nitrogen or sulfur heteroatoms are optionally oxidized. Illustrative examples of heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridinyl, pyridyl-N- oxide, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[b]thienyl, isobenzofuranyl, 2,3-dihydrobenzofuranyl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolinyl, indolinyl, cinnolinyl, pteridinyl, isothiazolyl.
Some of the heteroaryl groups present in the compounds of this invention are 5-6 membered monocyclic heteroaryl groups. Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms. Selected 6-membered heteroaryl groups contain 1 , 2, 3 or 4 nitrogen ring heteroatoms. Selected 5- or 6-membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and thiadiazolyl.
Some of the heteroaryl groups present in the compounds of this invention are 9-10 membered bicyclic heteroaryl groups. Selected 9-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms. Selected 10-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms. Selected 9-10 membered heteroaryl groups include benzo[b]thienyl, isobenzofuranyl, 2,3-dihydrobenzofuranyl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl.
In addition, the terms alkyl, aryl, cycloalkyl, heteroaryl, etc. may be used to define a divalent substituent, such as a group bonded to two other groups. In this instance, such terms are intended to encompass divalent moieties. For example, "pentyl" may be used to represent a pentylenyl diradical -wherein the pentyl moiety is any one of a divalent straight (e.g. -CH2CH2CH2CH2CH2-) or branched (e.g. -CH2CH(CH3)CH2CH2-,
-CH2CH2CH(CH2CH3)-, -CH2CH2C(CH3)2-) chain 5-carbon radical.
The terms "halogen" and "halo" represent chloro, fluoro, bromo or iodo
substituents.
The compounds of the invention are only those which are contemplated to be "chemically stable" as will be appreciated by those skilled in the art.
In one embodiment of the compounds of Formula (I), A is phenyl (phenylene), 6-membered, monocyclic or 9-10 membered, bicyclic heteroaryl (heteroarylene), or C5-7cylcloalkyl (cycloalkylene), wherein said phenyl, heteroaryl, or cycloalkyl is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen,
Figure imgf000008_0001
In another embodiment, A is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5- a]pyridinyl, or quinolyl, wherein said phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5- a]pyridinyl, or quinolyl is optionally substituted 1 -2 substituents each independently selected from the group consisting of Ci-4alkyl, C-^alkoxy, and halogen, specifically, each substituent is independently selected from the group consisting of methyl, methoxy and fluoro. In a further embodiment, A is unsubstituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinzolinyl.
In specific embodiments of the compounds of Formula (I) of this invention, m is 0 or m is 1 . In another embodiment, m is 2. In a further embodiment, m is 3 or 4.
In one embodiment, F is CONH. In another embodiment, F is NHCO. In a further embodiment, F is NHCOO (e.g., -NH-C(=0)0-). In other embodiments, F is NHCONR2, where R2 is hydrogen or Ci-2alkyl. In selected embodiments, F is CONH or NHCOO. In specific embodiments, F is NHCOO.
In one embodiment, n is 0, 1 , 2, or 3. In one specific embodiment, n is 0. In another specific embodiment, n is 1 . In a further specific embodiment, n is 2.
In one embodiment, Y is a bond, O, NR3, C(O), NR4C(0), or C(0)NR4, wherein R3 is H, Ci-2alkyl, or -COR3a, wherein R3a is Ci-3alkyl, haloCi-2alkyl, phenyl, or heterocyclyl, and R4 is H or C1-2alkyl.
In a specific embodiment of this invention, Y is a bond. In another embodiment, Y is C(O) or C(0)NR4, wherein R4 is H or C1-2alkyl.
In one embodiment, p is 0. In a further embodiment, p is 1 or 2 and R1 is H or phenyl. In yet another embodiment, p is 2, 3, or 4. In selected embodiments, p is 0.
In one embodiment, B is phenyl, naphthyl, 6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, or C5-7cycloalkyl, wherein said phenyl, naphthyl, heteroaryl, or cycloalkyi is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, hydroxy, Ci-3alkyl, Ci-3alkoxy, haloCi-2alkyl, haloCi-2alkoxy, Ci-3alkyl-carbonyl-, Ci-3alkoxy-carbonyl-,
Ci-3alkyl-carbonyl-oxy-,-CONR5R5, -S02NR5R5, -NR6R6, -Ci-4alkylNR6R6, phenyl, and 5-6 membered heterocyclyl, wherein:
said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, cyano, Ci_ 3alkyl, haloCi-2alkyl, Ci-3alkoxy, haloCi-2alkoxy, -NR6R6, and -C^alkylNR^6,
each R5 is independently selected from the group consisting of H and Ci-2alkyl; and
each R6 is independently selected from the group consisting of H, Ci-2alkyl,
C1-3alkyl-carbonyl-, and C1-3alkoxy-carbonyl-. In other embodiments, B is phenyl or pyridinyl, optionally substituted by C1-4alkyl, C1-4alkoxy, -C(0)NH2, -S02NH2, -C(0)OCH3, phenyl, pyridinyl, pyrrolidinyl, piperidinyl, morpholinyl, or -NRBaRBa, -C1-4alkylNR6R6, wherein each R6 is independently selected from the group consisting of H, Ci-2alkyl, and -C(0)CH3. In other embodiments, B is naphthyl, quinolyl, isoquinolyl, furo[3,2-c]pyridinyl, or 5,6,7, 8-tetrahydroquinolyl.
In a particular embodiment, the invention provides a compound of Formula (la):
Figure imgf000010_0001
or a salt thereof, wherein A, m, F, n and B are as defined herein.
Another particular embodiment of the invention provides a compound of Formula
(lb):
Figure imgf000010_0002
or a salt thereof, wherein X is a bond, O or NR2, where R2 is H or
Figure imgf000010_0003
specifically H or Ci-2alkyl, more specifically, R2 is hydrogen; and A, m, n and B are as defined herein.
A further particular embodiment of the invention provides a compound of Formula
(lc):
Figure imgf000010_0004
or a salt thereof, wherein A, m, X and B are as defined herein. A still further ula (Id):
Figure imgf000011_0001
or a salt thereof, wherein m, X, and B are as defined herein and S, T, V, and U are each independently selected from the group consisting of N or CH. In certain embodiments, two of S, T, V, and U are N and two are CH. In particular embodiments, one of S, T, V, and U is N and three are CH.
As used herein, the terms "compound(s) of the invention" or "compound(s) of this invention" mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a
pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
As used herein, the term "optionally substituted" means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and groups or rings substituted with one or more specified substituents.
The compounds according to Formula (I) may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as chiral carbon atoms, may also be present in a substituent such as an alkyl group. Where the stereochemistry of a chiral center present in Formula (I), or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof. Thus, compounds according to Formula (I) containing one or more chiral centers may be used as racemic mixtures, scalemic mixtures, or as diaseteromerically or enantiomerically pure materials.
Individual stereoisomers of a compound according to Formula (I) which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of
diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will appreciate that where the desired stereoisomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
When a disclosed compound or its salt is named or depicted by structure, it is to be understood that the compound or salt, including solvates (particularly, hydrates) thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof. The compound or salt, or solvates (particularly, hydrates) thereof, may also exhibit
polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs." It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
Because of their potential use in medicine, the salts of the compounds of
Formula (I) are preferably pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse,
J.Pharm.Sci (1977) 66, pp 1 -19. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
Typically, a salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
When a compound of the invention is a base (contain a basic moiety), a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like.
Suitable addition salts are formed from acids which form non-toxic salts and examples include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxynaphthoate, isethionate, itaconate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, /V-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmate, palmitate, pantothenate, phosphate/diphosphate, pyruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate.
Other exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, γ-hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene-1 -sulfonate and naphthalene-2-sulfonate.
If an inventive basic compound is isolated as a salt, the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pKa than the free base form of the compound.
When a compound of the invention is an acid (contains an acidic moiety), a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
Certain of the compounds of this invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety). The present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention, e.g., a hydrochloride salt, into another
pharmaceutically acceptable salt of a compound of this invention, e.g., a sulfate salt.
For solvates of the compounds of Formula (I), or salts thereof that are in crystalline form, the skilled artisan will appreciate that pharmaceutically-acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as
"hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates.
Because the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
The compounds of this invention may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist. The synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different substituent groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula (I), they are illustrative of processes that may be used to make the compounds of the invention. Intermediates (compounds used in the preparation of the compounds of the invention) may also be present as salts. Thus, in reference to intermediates, the phrase "compound(s) of formula (number)" means a compound having that structural formula or a pharmaceutically acceptable salt thereof.
Specific compounds of this invention are the compounds of Examples 1 -1 1 including salts, particularly pharmaceutically acceptable salts, thereof.
Other compounds that may be prepared using the methods described herein include: (6-acetamidopyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(dimethylamino)pyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-
3-yl)benzylcarbamate;
(2-(dimethylamino)pyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
methyl 5-((((2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methoxypyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methoxypyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-methylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-methylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)benzylcarbamate;
(6-carbamoylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-carbamoylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate; (6-sulfamoylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-phenylpyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
[2,3'-bipyridin]-5-ylmethyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
(6-morpholinopyridin-3-yl)methyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
quinolin-3-ylmethyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
isoquinolin-4-ylmethyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
furo[3,2-c]pyridin-7-ylmethyl 2-methoxy-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-acetamidopyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(dimethylamino)pyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
(2-(dimethylamino)pyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
methyl 5-((((2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methoxypyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methoxypyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-methylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate; (4-methylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-methylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)benzylcarbamate;
(6-carbamoylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-carbamoylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-sulfamoylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-phenylpyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
[2,3'-bipyridin]-5-ylmethyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-morpholinopyridin-3-yl)methyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
quinolin-3-ylmethyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
isoquinolin-4-ylmethyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
furo[3,2-c]pyridin-7-ylmethyl 2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-acetamidopyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(dimethylamino)pyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-(dimethylamino)pyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate; methyl 5-((((4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methoxypyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methoxypyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-methylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-methylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-carbamoylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-carbamoylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-sulfamoylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-phenylpyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
[2,3'-bipyridin]-5-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate; (6-(pyrrolidin-1-yl)pyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-morpholinopyridin-3-yl)methyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
quinolin-3-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate; isoquinolin-4-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate; furo[3,2-c]pyridin-7-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-acetamidopyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(dimethylamino)pyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-(dimethylamino)pyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
methyl 5-((((2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methoxypyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methoxypyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-methylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(4-methylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5-methylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-methylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-carbamoylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(2-carbamoylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-sulfamoylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-phenylpyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate; [2,3'-bipyridin]-5-ylmethyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(pyrrolidin-1 -yl)pyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-morpholinopyridin-3-yl)methyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
quinolin-3-ylmethyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
isoquinolin-4-ylmethyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
furo[3,2-c]pyridin-7-ylmethyl 2-fluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)benzylcarbamate;
(6-acetamidopyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)methyl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)methyl)carbamate;
methyl 5-(((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-(((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(4-methoxypyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(5-methoxypyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-methylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(4-methylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(5-methylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate; (2-methylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)methyl)carbamate;
(6-carbamoylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(2-carbamoylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-phenylpyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
[2,3'-bipyridin]-5-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)methyl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)methyl)carbamate;
(6-morpholinopyridin-3-yl)methyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
quinolin-3-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
isoquinolin-4-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl ((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)methyl)carbamate;
(6-acetamidopyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 5-yl)methyl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)methyl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)methyl)carbamate;
methyl 5-(((((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-(((((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamoyl)oxy)methyl)nicotinate; (6-methoxypyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(4-methoxypyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(5-methoxypyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(6-methylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(4-methylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(5-methylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(2-methylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)methyl)carbamate;
(6-carbamoylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 5-yl)methyl)carbamate;
(2-carbamoylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 5-yl)methyl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(6-phenylpyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
[2,3'-bipyridin]-5-ylmethyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)methyl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)methyl)carbamate;
(6-morpholinopyridin-3-yl)methyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 5-yl)methyl)carbamate;
quinolin-3-ylmethyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
isoquinolin-4-ylmethyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate; furo[3,2-c]pyridin-7-ylmethyl ((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)methyl)carbamate;
(6-acetamidopyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-
3-yl)phenyl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)phenyl)carbamate;
methyl 5-((((2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(4-methoxypyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5-methoxypyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-methylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(4-methylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5-methylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-methylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)phenyl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-phenylpyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate; [2,3'-bipyridin]-5-ylmethyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-morpholinopyridin-3-yl)methyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
quinolin-3-ylmethyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
isoquinolin-4-ylmethyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (2-methyl-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-acetamidopyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-2-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-2-yl)carbamate;
methyl 5-((((3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(4-methoxypyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(5-methoxypyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-methylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(4-methylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(5-methylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate; (2-methylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-2-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-phenylpyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-
2- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
quinolin-3-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
isoquinolin-4-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (3-methyl-5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-3-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-
3- yl)pyridin-3-yl)carbamate;
methyl 5-((((4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)nicotinate; (6-methoxypyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(4-methoxypyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5-methoxypyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-methylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(4-methylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5-methylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(2-methylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-
3-yl)pyridin-3-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-phenylpyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-
3-yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
quinolin-3-ylmethyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
isoquinolin-4-ylmethyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate; furo[3,2-c]pyridin-7-ylmethyl (4-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-
3-yl)pyridin-3-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-3-yl)carbamate;
methyl 5-((((2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(4-methoxypyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5-methoxypyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-methylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(4-methylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5-methylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(2-methylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)pyridin-3-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-phenylpyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate; [2,3'-bipyridin]-5-ylmethyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin- 3-yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
quinolin-3-ylmethyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
isoquinolin-4-ylmethyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (2-methyl-6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
methyl 5-((((6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-methylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(4-methylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(5-methylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate; (2-methylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-3-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin- 3-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
quinolin-3-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3-yl)carbamate; isoquinolin-4-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (6-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-3- yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)phenyl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)phenyl)carbamate;
methyl 5-((((2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate; (4-methoxypyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5-methoxypyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-methylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(4-methylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5-methylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-methylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)phenyl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-phenylpyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)phenyl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)phenyl)carbamate;
(6-morpholinopyridin-3-yl)methyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
quinolin-3-ylmethyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
isoquinolin-4-ylmethyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (2,6-difluoro-4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate; (6-acetamidopyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)quinolin-5-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)quinolin-5-yl)carbamate;
methyl 5-((((8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(6-methylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(4-methylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(5-methylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(2-methylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)quinolin-5-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate; (6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)quinolin-5-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)quinolin-5-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
quinolin-3-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5-yl)carbamate; isoquinolin-4-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (8-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)quinolin-5- yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
methyl 5-((((7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5-a]pyridin-4- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5-a]pyridin-4- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(4-methoxypyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(5-methoxypyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(6-methylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(4-methylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(5-methylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(2-methylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate; (6-carbamoylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(6-phenylpyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazolo[1 ,5-a]pyridin-4-yl)carbamate;
quinolin-3-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5-a]pyridin-4- yl)carbamate;
isoquinolin-4-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (7-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazolo[1 ,5- a]pyridin-4-yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
methyl 5-((((4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(4-methoxypyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate; (5-methoxypyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-methylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(4-methylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5-methylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-methylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-phenylpyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-morpholinopyridin-3-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
quinolin-3-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)carbamate; isoquinolin-4-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)carbamate; furo[3,2-c]pyridin-7-ylmethyl (4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)carbamate;
(6-acetamidopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate; (2-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(4-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(5-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(2-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyridin-2-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-
2-yl)carbamate; (6-morpholinopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2-yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyridin-2- yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazin-2-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazin-2-yl)carbamate;
methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(6-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(4-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(5-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(2-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazin-2-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate; (6-sulfamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazin-2-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrazin-2-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2-yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrazin-2- yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)carbamate;
methyl 5-((((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamoyl)oxy)methyl)picolinate;
methyl 5-((((2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-methylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(4-methylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate; (5-methylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(2-methylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-5-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 5-yl)carbamate;
quinolin-3-ylmethyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
isoquinolin-4-ylmethyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-5- yl)carbamate;
(6-acetamidopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(6-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-2-yl)carbamate;
(2-(dimethylamino)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-2-yl)carbamate;
methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamoyl)oxy)methyl)picolinate; methyl 5-((((5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamoyl)oxy)methyl)nicotinate;
(6-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(4-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(5-methoxypyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(6-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(4-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(5-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(2-methylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(5,6,7,8-tetrahydroquinolin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-2-yl)carbamate;
(6-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(2-carbamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(6-sulfamoylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(6-phenylpyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
[2,3'-bipyridin]-5-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
(6-(pyrrolidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-2-yl)carbamate;
(6-(piperidin-1-yl)pyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)pyrimidin-2-yl)carbamate;
(6-morpholinopyridin-3-yl)methyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin- 2-yl)carbamate;
quinolin-3-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate; isoquinolin-4-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
furo[3,2-c]pyridin-7-ylmethyl (5-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)pyrimidin-2- yl)carbamate;
and salts, particularly pharmaceutically acceptable salts, thereof.
Compound names were generated using the software naming program
ChemDraw 1 1.0 available from CambridgeSoft Corporation, 100 CambridgePark Drive, Cambridge, MA 02140, USA (http://www.cambridgesoft.com).
The compounds of Formula (I) can be prepared according to the methods outlined below.
Figure imgf000040_0001
The invention also includes various deuterated forms of the compounds of
Formula (I). Each available hydrogen atom attached to a carbon atom may be
independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of Formula (I). For example, deuterated alkyl groups (e.g., /V-(deutero-methyl) amines) may be prepared by conventional techniques (see for example: methyl-c/3-amine available from Aldrich Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2). Employing such compounds will allow for the preparation of compounds of Formula (I) in which various hydrogen atoms of the /V-methyl groups are replaced with a deuterium atom.
The present invention is directed to a method of inhibiting an HDAC which comprises contacting the acetylase with a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. More specifically, this invention is directed to a method of inhibiting HDAC comprising contacting a cell with an effective amount of a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of an HDAC-mediated disease or disorder comprising administering a therapeutically effective amount of the compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof. As used herein, "patient" refers to a mammal, specifically, a human. A therapeutically "effective amount" is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
Thus, e.g., a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to inhibit the activity of HDAC such that a disease condition which is mediated by that activity is reduced, alleviated or prevented. The amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC50), efficacy (EC50), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art. Likewise, the duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can
nevertheless be determined by one of skill in the art.
"Treating" or "treatment" is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by HDAC. The methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
In one embodiment, this invention is directed to a method of treating, ameliorating, or preventing an autoimmune disorder, an immunological disease, an inflammatory disorder, transplant/graft rejection (e.g., allograft), lymphopenia, or graft-versus-host disease (GvHD) in a patient, specifically in a human, comprising administering to the patient a compound of this invention, in an amount sufficient to increase the level and/or activity of a Treg cell or a population of Treg cells in the patient, thereby treating, ameliorating, or preventing the autoimmune disorder, inflammatory disorder,
transplant/graft rejection, lymphopenia, or GvHD in the patient.
Additional examples of diseases and conditions that may be treated by the compounds of this invention include but not limited to type II diabetes mellitus, coronary artery disease, alopecia, allergies and allergic reactions, and sepsis/toxic shock.
Exemplary autoimmune disorders include, but are not limited to, multiple sclerosis, juvenile idiopathic arthritis, psoriatic arthritis, hepatitis C virus-associated mixed cryoglobulinemia, polymyositis, dermatomyositis, polyglandular syndrome type II, autoimmune liver disease, Kawasaki disease, myasthenia gravis, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX (syndrome)), type I diabetes, psoriasis, hypothyroidism, hemolytic anemia, autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED), thrombocytopenia, spondyloarthritis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, eczema, gastritis, or thyroiditis. As part of a nonlimiting list, the inflammatory disorder can be contact hypersensitivity, atopic dermatitis or Still disease.
Additional examples of autoimmune diseases include but are not limited to autoimmune diseases include osteoarthritis, systemic sclerosis, sarcoidosis, insulin dependent diabetes mellitus (IDDM, type I diabetes), reactive arthritis, scleroderma, vasculitis, Wegener's granulomatosis, Hashimoto's disease, scleroderma, oophoritis, Lupus (SLE), Grave's disease, asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
Examples of transplant/graft rejection (e.g., allograft), lymphopenia, or graft- versus-host disease (GvHD) are those arising from cell, tissue and organ transplantation procedures, such as therapeutic cell transplants such as stem cells, muscle cells such as cardiac cells, islet cells, liver cells, bone marrow transplants, skin grafts, bone grafts, lung transplants, kidney transplants, liver transplants, and heart transplants.
In another embodiment, this invention is directed to a method of treating an HDAC-mediated neurodegenerative disease or disorder which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of a neurodegenerative disease or disorder associated with deacetylases, such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
Other examples of diseases and conditions that may be treated by the compounds of this invention include but are not limited to cystic fibrosis, osteoporosis, obesity, epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia, cardiac disease (e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation of infarct size in acute coronary syndrome), diseases or disorders involving muscular atrophy, gentamicin-induced hearing loss, drug resistance (e.g., drug resistance in osteosarcoma and colon cancer cells), infectious diseases, and immune deficiency/immunocompromised patients. Examples of infectious diseases relate to various pathogen infections such as viral, fungal, bacterial, mycoplasm, and infections by unicellular and multicellular eukaryotic organisms. Common human pathogens include but are not limited to HIV, HSV, HPV, Hepatitis A, B and C viruses, influenza, denge, zostrella, rubella, RSV, rotavirus, gram positive, gram negative, streptococcus, tetanus, staphalococcus, tuberculosis, listeria, and malaria.
The compounds of the invention may be employed alone or in combination with standard anti-cancer regimens for neoplastic cell, e.g., tumor cell and cancer cell, treatments. Thus, in another embodiment, this invention is directed to inhibitors of HDAC and their use to stop or reduce the growth of neoplastic cells, e.g., cancer cells and tumor cells. The growth of cancer cells and/or tumor cells that are found in the following cancer types may be reduced by treatment with a compound of this invention: carcinoma (e.g., adenocarcinoma), heptaocellular carcinoma, sarcoma, myeloma (e.g., multiple myeloma), treating bone disease in multiple myeloma, leukemia, childhood acute lymphoblastic leukemia and lymphoma (e.g., cutaneous cell lymphoma), and mixed types of cancers, such as adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, and teratocarcinoma. In one aspect of the invention, breast or prostate cancers or tumors are treated using the HDAC inhibitors of this invention. Other cancers that may be treated using the compounds of this invention include, but are not limited to, bladder cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, endometrial cancer, pancreatic cancer, cervical cancer, ovarian cancer; head and neck cancer, and melanoma.
The present invention is further directed to a method of treating a B-cell lymphoma, particularly a B-cell lymphoma associated with deacetylases, which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof. Examples of B-cell lymphomas associated with deacetylases that may be treated using the method of this invention include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and
Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma). More specifically, this invention is directed to a method of treatment of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
The compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
Parenteral administration refers to routes of administration other than enteral,
transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages. Topical administration includes application to the skin.
The compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
Treatment of HDAC-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other agents, for example, in combination with one or more of the following agents: DNA methyltransferase inhibitors, acetyl transferase enhancers, proteasome or HSP90 inhibitors, and one or more immunosuppressants that do not activate the T suppressor cells including but are not limited to corticosteroids, rapamycin, Azathioprine, Mycophenolate, Cyclosporine, Mercaptopurine (6-MP), basiliximab, daclizumab, sirolimus, tacrolimus, Muromonab-CD3, cyclophosphamide, and
methotrexate, which are administered in effective amounts as is known in the art.
The compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
The pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection. Alternatively, the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form. For oral application, for example, one or more tablets or capsules may be administered. A dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula (I) or a salt, particularly a pharmaceutically acceptable salt, thereof). When prepared in unit dosage form, the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
The pharmaceutical compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
As used herein, "pharmaceutically-acceptable excipient" means a material, composition or vehicle involved in giving form or consistency to the composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided. In addition, each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
The compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration. Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will appreciate that certain pharmaceutically-acceptable excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation.
Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention. In addition, there are a number of resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
The pharmaceutical compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
Company).
In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention.
In the following experimental descriptions, the following abbreviations may be used: Abbreviation Meaning
AcOH acetic acid
aq aqueous
brine saturated aqueous NaCI
CH2CI2 methylene chloride
CH3CN or MeCN acetonitrile
CH3NH2 methylamine
d day
DMF Λ/,/ν-dimethylformamide
DMSO dimethylsulfoxide
equiv equivalents
Et ethyl
Et3N triethylamine
Et20 diethyl ether
EtOAc ethyl acetate
h, hr hour
HCI hydrochloric acid
/-Pr2NEt Λ/',/ν -diisopropylethylamine
KOf-Bu potassium ferf-butoxide
LCMS liquid chromatography-mass spectroscopy
Me methyl
MeOH or CH3OH methanol
MgS04 magnesium sulfate
min minute
MS mass spectrum
μνν microwave
NaBH4 sodium borohydride
Na2C03 sodium carbonate
NaHCOs sodium bicarbonate
NaOH sodium hydroxide
Na2S04 sodium sulfate
NH4CI ammonium chloride
NiCI2-6H20 nickel (II) chloride hexahydrate
NMP /v-methyl-2-pyrrolidone
Ph phenyl
rt room temperature
satd saturated
sex strong cation exchange
SPE solid phase extraction
TFA trifluoroacetic acid
THF tetrahydrofuran
fR retention time
Figure imgf000049_0001
2-(4-(5-(Trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetic acid: A solution of 2-(4- cyanophenyl)acetic acid (2 g, 12.41 mmol) and hydroxylamine (50% in H20) (1.901 ml_, 31 .0 mmol) was refluxed in ethanol (40 ml.) overnight. The reaction was concentrated under reduced pressure and dried overnight in a vacuum oven. The resulting white solid was taken up in THF (40 ml_), and Et3N (3.87 ml_, 27.8 mmol) and TFAA (3.87 ml_, 27.8 mmol) were added at 0 °C. The reaction was allowed to warm to rt and stirred for 24 h. The reaction mixture was concentrated under reduced pressure, and the residue taken up in water. The aqueous phase was extracted with DCM, and the combined organic layers were dried over Na2S04, filtered, and concentrated under reduced pressure. The crude product was taken on without purification as a waxy cream solid (3.27 g, 12.02 mmol, 96% yield). 1H NMR (400 MHz, METHANOL-^) δ 8.08 (d, J = 8.22 Hz, 2H), 7.51 (d, J = 8.22 Hz, 2H), 3.72 (s, 2H), LCMS: fR = 0.83 min, 92%. MS m/z = 542 (M+H)+.
Figure imgf000049_0002
A -Phenyl-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide: Aniline (0.018 ml_, 0.202 mmol), HATU (77 mg, 0.202 mmol) and /'-Pr2NEt (0.096 ml_, 0.551 mmol) were added to a solution of 2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetic acid (50 mg, 0.184 mmol) in DMF (1 ml.) . The reaction was stirred at rt for 2 h. The reaction was purified by reverse phase prep-HPLC (20% - 100% MeCN in water with 0.05% TFA) to yield the title compound (16.9 mg, 0.049 mmol, 27% yield). 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.18 (d, J = 7.83 Hz, 2H), 7.43 - 7.63 (m, 4H), 7.10 - 7.43 (m, 3H), 3.85 (s, 2H), LCMS: fR = 0.94 min, 100%. MS m/z = 348 (M+H)+.
Figure imgf000050_0001
A -Cyclopentyl-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1 was used to yield the title compound (13.2 mg, 0.039 mmol, 21 % yield). 1 H NMR (400 MHz,
METHANOL-^) δ ppm 8.05 (d, J = 8.42 Hz, 2 H), 7.49 (d, J = 8.22 Hz, 2 H), 4.09 (t, J = 6.66 Hz, 1 H), 3.56 (s, 2 H) 1.86 - 1.99 (m, 2 H), 1 .53 - 1.78 (m, 4 H), 1.40 - 1.52 (m, 2 H), LCMS: fR = 0.91 min, 100%. MS m/z = 340 (M+H)+.
Figure imgf000050_0002
A -(Pyridin-4-ylmethyl)-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (15.4 mg, 0.043 mmol, 23 % yield). 1H NMR (400 MHz, METHANOL-^) δ ppm 8.70 (d, J = 6.07 Hz, 2H), 8.10 (d, J = 8.03 Hz,
2H), 7.82 (d, J = 6.07 Hz, 2H), 7.55 (d, J = 8.22 Hz, 2H), 4.63 (s, 2H), 3.76 (s, 2H), LCMS: fR = 0.60 min, 100%. MS m/z = 363 (M+H)+.
Figure imgf000050_0003
A -Benzyl-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (9.4 mg, 0.026 mmol, 14 % yield). 1 H NMR (400 MHz, METHANOL-^) δ ppm 8.07 (d, J = 8.22 Hz, 2H), 7.51 (d, J = 8.03 Hz, 2H), 7.18 - 7.33 (m, 5H), 4.37 (s, 2H), 3.65 (s, 2H), LCMS: fR = 0.91 min, 98%. MS m/z = 362 (M+H)+.
Figure imgf000051_0001
A -(4-Methoxybenzyl)-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (23.9 mg, 0.061 mmol, 21 % yield). 1H NMR (400 MHz,
CHLOROFORM-d) δ ppm 8.13 (d, J = 7.83 Hz, 2H), 7.49 (d, J = 7.83 Hz, 2H), 7.19 (d, J = 8.22 Hz, 2H), 6.88 (d, J = 8.03 Hz, 2H), 4.41 (d, J = 5.48 Hz, 2H), 3.83 (s, 3H), 3.71 (s, 2H), LCMS: fR = 0.90 min, 98%. MS m/z = 362 (M+H)+.
Figure imgf000051_0002
A -(3,4-Dimethoxyphenethyl)-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (9.9 mg, 0.023 mmol, 8% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.1 1 (d, J = 8.03 Hz, 2H), 7.40 (d, J = 8.03 Hz, 2H), 6.76 (d, J = 8.03 Hz, 1 H), 6.67 (s, 1 H), 6.60 (d, J = 8.03 Hz, 1 H), 3.87 (d, J = 6.07 Hz, 6H), 3.64 (s, 2H), 3.54 (q, J = 6.46 Hz, 2H), 2.75 (t, J = 6.75 Hz, 2H), LCMS: fR = 0.87 min, 98%. MS m/z = 436 (M+H)+.
Figure imgf000052_0001
A -Cyclohexyl-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (39.5 mg, 0.1 12 mmol, 38% yield). 1H NMR (400 MHz,
CHLOROFORM-d) δ ppm 8.12 (d, 2H), 7.47 (d, J = 7.63 Hz, 2H), 5.50 (br. s., 1 H), 3.73 - 3.90 (m, 1 H), 3.63 (s, 2H), 1 .55 - 1.96 (m, 5H), 1.37 (q, J = 1 1.94 Hz, 2H), 0.99 - 1.23 (m, 3H), LCMS: fR = 0.94 min, 100%. MS m/z = 354 (M+H)+.
Figure imgf000052_0002
A -(Pyridin-2-ylmethyl)-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (10.5 mg, 0.029 mmol, 10% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.80 (br. s., 1 H), 8.73 (d, J = 5.48 Hz, 1 H), 8.39 (t, J = 7.73 Hz, 1 H), 7.99 - 8.14 (m, 3H), 7.85 (t, J = 6.56 Hz, 1 H), 7.45 (d, J = 8.22 Hz, 2H), 4.78 (d, J = 5.87 Hz, 2H), 3.72 (s, 2H), LCMS: fR = 0.65 min, 100%. MS m/zm/z = 363 (M+H)+
Figure imgf000052_0003
A -(Cyclohexylmethyl)-2-(4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)phenyl)acetamide: The general procedure for the synthesis of amides as described in example 1was used to yield the title compound (22.8 mg, 0.062 mmol, 21 % yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.14 (d, J = 8.03 Hz, 2H), 7.49 (d, J = 8.03 Hz, 2H), 5.56 (br. s., 1 H), 3.68 (s, 2H), 3.12 (t, J = 6.46 Hz, 2H), 1.61 - 1.83 (m, 6H), 1.45 (ddd, J = 10.77, 7.24, 3.72 Hz, 1 H), 1.07 - 1.30 (m, 2H), 0.82 - 0.98 (m, 2 H). LCMS: fR = 1.00 min, 96%. MS m/z = 368 (M+H)+.
Figure imgf000053_0001
Pyridin-3-ylmethyl 4-cyanobenzylcarbamate: Pyridin-3-ylmethanol (0.546 g, 5 mmol) in THF (2ml) was added to a suspension of 1 , 1 '-carbonyldiimidazole (0.81 1 g, 5.00 mmol) in THF (8ml) at 10 °C. The mixture was stirred for 1 h at rt. The resultant solution was added to the solution of 4-(aminomethyl)benzonitrile (0.661 g, 5.00 mmol), DBU (0.754 ml_, 5.00 mmol), and Et3N (0.697 ml_, 5.00 mmol) in THF (10 ml). The reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure, and the residue was partitioned between EtOAc and water. The organic layer was separated, washed with water and brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was recrystallized in EtOAc/hexanes to afford the title compound as a white solid (0.85 g, 63%). 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1 H), 8.57 (d, J = 3.91 Hz, 1 H), 8.03 (t, J = 5.87 Hz, 1 H), 7.75 - 7.89 (m, 3H), 7.40 - 7.52 (m, 3H), 5.12 (s, 2H), 4.32 (d, J = 6.07 Hz, 2H). LCMS: fR = 0.44 min, 88%.. MS (ESI): m/z 268 (M+H)+.
Figure imgf000053_0002
Pyridin-3-ylmethyl 4-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)benzylcarbamate:
Hydroxylamine hydrochloride (0.083 g, 1.200 mmol) and /'-Pr2NEt (0.262 ml, 1.5 mmol) were added to a suspension of pyridin-3-ylmethyl 4-cyanobenzylcarbamate (0.273 g, 1 mmol) in ethanol (15 ml.) with a few milligrams of 8-hydroxyquinoline . The resultant mixture was heated under gentle reflux for 4-5 h, cooled, and concentrated to dryness under reduced pressure. The residue was dissolved in THF (10 ml_). /'-Pr2NEt (0.437 ml_, 2.500 mmol), TFAA (0.424 ml_, 3.00 mmol), and a few milligrams of DMAP were added sequentially. The resultant reaction mixture was stirred for 5 h at rt, heated at 50 °C overnight, and concentrated under reduced pressure. The residue was directly purified by silica gel column chromatography (0% - 80% EtOAc/hexanes) to afford the title compound as a light yellow solid (0.32g, 85%). 1H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1 H), 8.57 (d, J = 1 Hz, 1 H), 7.99 - 8.1 1 (m, 3H), 7.82 (d, J = 7.83 Hz, 1 H), 7.52 (d, J = 8.22 Hz, 2H), 7.45 (dd, J = 4.89, 7.63 Hz, 1 H), 5.14 (s, 2H), 4.34 (d, J = 6.07 Hz, 2H). 19F NMR (376 MHz, DMSO-d6) 5 -65.1 . LCMS: fR = 0.68 min, 100%. MS (ESI): m/z 379 (M+H)+.
Figure imgf000054_0001
6-(Diethylcarbamoyl)-2-naphthoic acid: EDC (6.69 g, 34.9 mmol) was added to a solution of naphthalene-2,6-dicarboxylic acid (7.55 g, 34.9 mmol and HOBT (5.35 g, 34.9 mmol) in DMF (500 ml_). The mixture was stirred at rt for 2 h, and diethylamine (10.83 ml_, 105 mmol) was added. The mixture was stirred at rt overnight and then concentrated under reduced pressure. The crude product was treated with 1 N HCI (170 ml) and EtOAc (170 ml), insoluble compound was filtered off, and the phases were separated. The organic phase was extracted with 5% Na2C03 (3 X 70 ml), the combined aqueous extracts were acidified with concentrated HCI and extracted with EtOAc (3 X 170 ml). The combined organic extracts were concentrated under reduced pressure, and the residue was treated with 1 N HCI and extracted with EtOAc. The organic solution was washed with 1 N HCI and brine, dried over Na2S04, and filtered to give the title compound (3.5 g, 12.9 mmol, 36.9 % yield). Material was taken on to the next step without further purification. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 10.20 (br. s., 1 H), 8.73 (s, 1 H), 8.19 (dd, J = 8.61 , 1 .17 Hz, 1 H), 8.04 (d, J = 8.42 Hz, 1 H), 7.91 - 8.00 (m, 2 H), 7.58 (d, J = 8.42 Hz, 1 H), 3.67 (br. s., 2 H), 3.36 (br. s., 2 H), 1.07 - 1 .50 (m, 6 H). LCMS: fR = 0.64 min, 91 %. MS m/z = 270 (M-H)\
Figure imgf000054_0002
(6-((Diethylamino)methyl)naphthalen-2-yl)methanol: LAH (2 N in THF, 23.5 ml_, 47.0 mmol) was added to a solution of 6-(diethylcarbamoyl)-2-naphthoic acid (3.38 g, 12.46 mmol) in THF (50 mL) at 0 °C . The reaction was warmed up and refluxed for 1 h. The solution was cooled down to 0 °C and treated with satd. potassium sodium tartrate solution and EtOAc. The solid was filtered off, and two phases of the filtrate were separated. The aqueous solution was further extracted with EtOAc. The organic solution volume was reduced under reduced pressure, and extracted with 1 N HCI. The combined aqueous solution was basified with 33% NaOH solution and extracted with EtOAc. The combined organic solution was washed with brine, dried over Na2S04, filtered, and concentrated under reduced pressure to give the title compound as a yellow oil (2.2 g, 9.04 mmol, 72.6 % yield). Material was taken on to the next step without further purification. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.74 - 7.95 (m, 4 H), 7.54 (m, 2 H), 4.90 (s, 2 H), 3.77 (s, 2 H), 2.62 (q, J = 7.1 1 Hz, 4 H), 1 .12 (t, J = 7.15 Hz, 6 H). L = 0.39 min, 98%. MS m/z = 244 (M+H)+.
Figure imgf000055_0001
(6-((Diethylamino)methyl)naphthalen-2-yl)methyl (4-cyanophenyl)carbamate, trifluoroacetic acid salt: A solution of (6-((diethylamino)methyl)naphthalen-2-yl) (450 mg, 1 .849 mmol) and bis(2,5-dioxopyrrolidin-1 -yl) carbonate (474 mg, 1.849 mmol) in MeCN (4 mL) was stirred at rt overnight. The solvent was removed, and the crude intermediate was dissolved in THF (4.00 mL). 4-Aminobenzonitrile (218 mg, 1 .849 mmol) and Na2C03 (196 mg, 1 .849 mmol) were added to this solution, and the mixture was stirred at rt for two days. The solution was concentrated under reduced pressure and purified via reverse phase prep-HPLC (10% - 100% MeCN in water with 0.05% TFA) to give the title compound as a yellow oil (108 mg, 0.215 mmol, 1 1.65 % yield). 1H NMR (400 MHz, METHANOL-^) δ ppm 7.93 - 8.09 (m, 4 H), 7.53 - 7.71 (m, 6 H), 5.40 (s, 2 H), 4.51 (s, 2 H), 3.20 - 3.28 (m, 4 H), 1 .37 (t, J = 7.34 Hz, 6 H). 19F NMR (376 MHz,
METHANOL-^) δ ppm -77.42. LCMS: fR = 0.63 min, 92%. MS m/z = 388 (M+H)+.
Figure imgf000055_0002
((6-((Diethylamino)methyl)naphthalen-2-yl)methyl (4-(Λ - hydroxycarbamimidoyl)phenyl)carbamate, trifluoroacetic acid salt:
Hydroxylamine (50% aqueous solution) (42.7 mg, 0.646 mmol) was added to a solution of (6-((diethylamino)methyl)naphthalen-2-yl)methyl (4-cyanophenyl)carbamate 2,2,2- trifluoroacetate (108 mg, 0.215 mmol) in ethanol (2 mL) . The mixture was stirred at 85 °C for 2 h and concentrated under reduced pressure and dried to give the title compound (100 mg, 0.187 mmol, 87 % yield). Material was taken on to the next step without further purification. 1H NMR (400 MHz, METHANOL-^) δ ppm 7.90 - 8.06 (m, 4 H), 7.42 - 7.72 (m, 6 H), 5.38 (s, 2 H), 4.43 (s, 2 H), 3.18 (q, J = 7.24 Hz, 4 H), 1 .34 (t, J = 7.24 Hz, 6 H). 19F NMR (376 MHz, METHANOL-^) δ ppm -77.34. LCMS: fR = 0.41 min, 78%. MS m/z = 42 +H)+.
Figure imgf000056_0001
(6-((Diethylamino)methyl)naphthalen-2-yl)methyl (4-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)phenyl)carbamate, trifluoroacetic acid salt: TFAA (0.060 mL, 0.430 mmol) was added to a solution of (6-((diethylamino)methyl)naphthalen-2-yl)methyl (4-(N- hydroxycarbamimidoyl)phenyl)carbamate 2,2,2-trifluoroacetate (1 15 mg, 0.215 mmol) and Et3N (0.075 mL, 0.538 mmol) in THF (1.5 mL) at 0 °C. The mixture was stirred at rt over the weekend, concentrated under reduced pressure, and purified via reverse phase prep- HPLC (15% - 100% MeCN in water with 0.05% TFA) to give the title compound as a light brown oil (71 mg, 0.1 16 mmol, 53.9 % yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (s, 1 H), 9.51 (br. s., 1 H), 7.97 - 8.19 (m, 6 H), 7.59 - 7.84 (m, 4 H), 5.42 (s, 2 H), 4.51 (d, J = 5.29 Hz, 2 H), 3.16 (dd, J = 1 1.75, 7.24 Hz, 4 H), 1.28 (t, J = 7.24 Hz, 6 H). 19F NMR (376 MHz, DMSO-de) δ ppm -65.09, -73.74. LCMS: fR = 0.81 min, 100%. MS m/z = 499 (M+H)+.
Pharmaceutical Compositions
Example A
Tablets are prepared using conventional methods and are formulated as follows:
Ingredient Amount per tablet
Compound I 5mg
Microcrystalline cellulose 100mg
Lactose 100mg
Sodium starch glycollate 30mg
Magnesium stearate 2mg
Total 237mg Example B
Capsules are prepared using conventional methods and are formulated as follows:
Inqredient Amount per tablet
Compound 15mg
Dried starch 178mg
Maqnesium stearate 2mq
Total 195mg
Histone Deacetylase 9 (HDAC9) Inhibition Assay:
Novel histone deacetylase 9 (HDAC9) inhibitors were characterized in an in vitro biochemical functional assay. The assay measures the increased fluorescent signal due to deacetylation, by HDAC9, of a fluorogenic substrate. The commercial available substrate is Class lla HDAC-specific and contains an acetylated lysine residue and would releases the fluorescent signal upon trypsin cleavage after deacetylation.
Specifically, test compounds diluted to various concentrations in 100% DMSO are first dispensed into 384-well assay plates. Recombinant HDAC9 isoform 4 (purchased from BPS Bioscience) in complete assay buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1 mM MgCI2, 0.05% BSA & 0.005% Tween 20) were then added to each well (5uL/well) using Multidrop Combi (Thermo Scientific), followed by 5 uL/well substrate (purchased from BPS Bioscience, 4.5 uM final). After 45 minutes incubation at room temperature, 10uL 2x developer solution (assay buffer with 40 uM Trypsin and 20 uM Trichostatin A) was added. The plates were then incubated 1 hour at room temperature before reading in fluorescent intensity mode at 450nm in an Envision (Perkin Elmer) plate reader. Percent Inhibition of HDAC9 activity by compounds in each test wells was calculated by normalizing to fluorescent signal in control wells containing DMSO only. The plC50s value of test compounds were calculated from non-linear curve fitting, using ActivityBase5 data analysis tool (IDBS), from 1 1 point 3x dilution series starting from 100 uM final compound concentration.
For concentration/dose response experiments, normalized data were fit and plC50s determined using conventional techniques. The plC50s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compound of Examples 1 -1 1 exhibited a plC50 between 5.0 and 9.0 e.g., for example, the compound of Examples 1 , 2, 3 and 4 inhibited HDAC9 in the above method with a mean plC50 > 6.
References:
US 20060269559, US Patent No. 7,521 ,044, WO2007084775
"Deacetylase inhibition promotes the generation and function of regulatory T cells," R.Tao, E. F. de Zoeten, E. O" zkaynak, C. Chen, L. Wang, P. M. Porrett, B. Li, L. A. Turka, E. N. Olson, M. I. Greene, A. D. Wells, W. W. Hancock, Nature Medicine, 13 (1 1 ), 2007.
"Expression of HDAC9 by T Regulatory Cells Prevents Colitis in Mice," E. F. de
Zoeten, L. Wang, H. Sai, W. H. Dillmann, W. W. Hancock, Gastroenterology. 2009 Oct 28.
"Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells," L. Wang, E. F. de Zoeten, M. I. Greene and W. W.
Hancock, Nature Review Drug Discovery. 8(12):969-81 , 2009 and references therein.
"HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival," L. Wang, et al., Am. J. Transplant 9, S621 (2009).
"Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes," A. Nebbioso, F. Manzo, M. Miceli, M. Conte, L. Manente, A. Baldi, A. De Luca, D. Rotili, S. Valente, A. Mai, A. Usiello, H.
Gronemeyer, L. Altucci, EMBO reports 10 (7) , 776-782, 2009. and references therein.
"Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender- Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor," E. van Rooij, J. Fielitz, L. B. Sutherland, V. L. Thijssen, H. J. Crijns, M. J. Dimaio, J. Shelton, L. J. De Windt, J. A. Hill, E.N. Olson, Circulation Research, Jan 2010.

Claims

What is claimed is:
1. A compound according to Formula I:
Figure imgf000059_0001
wherein:
A is aryl, 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, or C3-i4cycloalkyl, wherein said aryl, heteroaryl, or cycloalkyi, is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, Ci-4alkyl, Ci-4alkoxy, Ci-4alkylthio, haloCi-4alkyl, haloCi-4alkyloxy,
Figure imgf000059_0002
Ci-4alkoxy-carbonyl-,
Figure imgf000059_0003
m is 0, 1 , 2, 3, or 4;
F is CONH, NHCO, NHCOO or NHCONR2, where R2 is hydrogen or C1-4alkyl; n is 0, 1 , 2, 3, or 4;
Y is a bond, O, S, NR3, C(O), NR4C(0), or C(0)NR4, wherein R3 is H, C^alkyl, or -COR3a, wherein R3a is
Figure imgf000059_0004
phenyl, or heterocyclyl, and R4 is H or Ci-4alkyl;
wherein when n is 1 and F is CONH, NHCOO or NHCONR2, then Y is selected from the group consisting of a bond, C(O), and C(0)NR4;
p is 0, 1 , 2, 3, or 4;
R1 is H, phenyl or 5-6 membered heteroaryl, wherein said phenyl or heteroaryl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, C-|-4alkyl, haloC-|-4alkyl, C-|-4alkoxy, haloC-|-4alkoxy, -NR5R5 and -(C 4alkyl)NR5R5;
B is aryl, 5-6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, C3-i4cycloalkyl, adamantyl, or 5-6 membered heterocyclyl, wherein said aryl, heteroaryl, C3-i4cycloalkyl, adamantyl, or heterocyclyl is optionally substituted by 1 -4 substituents each independently selected from the group consisting of halogen, nitro, cyano, hydroxy, Ci-4alkyl,
Figure imgf000059_0005
Ci-4alkoxy-carbonyl-, C^alkyl-carbonyl-oxy-, C1-4alkylthio, -CONR5R5, -SOrNR5R5, -NR6R6, -Ci-4alkylNR6R6, phenyl, and 5-6 membered heterocyclyl,
wherein
r is 1 or 2, said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, C-i. 4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, -NR6R6, and -C1-4alkylNR6R6,
each R5 is independently selected from the group consisting of H and Cr4alkyl; and
each R6 is independently selected from the group consisting of H, d^alkyl, Ci-4alkyl-carbonyl-, and
Figure imgf000060_0001
or a salt thereof.
2. The compound or salt according to claim 1 , wherein A is phenyl, 6-membered, monocyclic or 9-10 membered, bicyclic heteroaryl, or C5-7cylcloalkyl, wherein said phenyl, heteroaryl, or cycloalkyi is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, d^alkyl, Ci-4alkoxy, haloCi-4alkyl, and haloCi-4alkoxy.
3. The compound or salt according to claim 1 , wherein A is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinolyl, wherein said phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinolyl is optionally substituted 1 -2 substituents each independently selected from the group consisting of C1-4alkyl,
C1-4alkoxy, and halogen.
4. The compound or salt according to claim 3, wherein said phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinolyl is optionally substituted 1 -2 substituents each independently selected from the group consisting of methyl, methoxy and fluoro.
5. The compound or salt according to claim 1 , A is unsubstituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolo[1 ,5-a]pyridinyl, or quinzolinyl.
6. The compound or salt according to any one of claims 1 -5, wherein m is 0.
7. The compound or salt according to any one of claims 1 -5, wherein m is 1.
8. The compound or salt according to any one of claims 1 -5, wherein m is 2.
9. The compound or salt according to any one of claims 1 -8, wherein F is CONH.
10. The compound or salt according to any one of claims 1-8, wherein F is NHCO.
1 1 . The compound or salt according to any one of claims 1-8, wherein F is NHCOO.
12. The compound or salt according to any one of claims 1-8, wherein F is NHCONR2, where R2 is hydrogen or d-2alkyl.
13 The compound or salt according to any one of claims 1-12, wherein n is 0, 1 ,
2, or 3.
14 The compound or salt according to any one of claims 1-12, wherein n is 0.
15 The compound or salt according to any one of claims 1-12, wherein n is 1.
16 The compound or salt according to any one of claims 1-12, wherein n is 2.
17. The compound or salt according to any one of claims 1-16, wherein Y is a bond, O, NR3, C(O), NR4C(0), or C(0)NR4, wherein R3 is H, C1-2alkyl, or -COR3a, wherein R3a is C1-3alkyl, haloC1-2alkyl, phenyl, or heterocyclyl, and R4 is H or C1-2alkyl.
18. The compound or salt according to any one of claims 1-16, wherein Y is a bond.
19. The compound or salt according to any one of claims 1 -16, wherein Y is C(O) or C(0)NR4, wherein R4 is H or C1-2alkyl.
20. The compound or salt according to any one of claims 1-19, wherein p is 0.
21 . The compound or salt according to any one of claims 1-19, wherein p is 1 or 2 and R1 is H or phenyl.
22. The compound or salt according to any one of claims 1-21 , wherein B is phenyl, naphthyl, 6 membered, monocyclic or 9-10 membered, bicyclic heteroaryl, or
C5-7cycloalkyl, wherein said phenyl, naphthyl, heteroaryl, or cycloalkyl is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, cyano, hydroxy, C1-3alkyl, C1-3alkoxy, haloC1-2alkyl, haloC1-2alkoxy,
C1-3alkyl-carbonyl-, C1-3alkoxy-carbonyl-, C1-3alkyl-carbonyl-oxy-,-CONR5R5, -S02NR5R5, -NR6R6, -Ci-4alkylNR6R6, phenyl, and 5-6 membered heterocyclyl, wherein:
said phenyl or 5-6 membered heterocyclyl is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, cyano, Ci. 3alkyl, haloCi-2alkyl, Ci-3alkoxy, haloCi-2alkoxy, -NR6R6, and -C^alkylNR^6,
each R5 is independently selected from the group consisting of H and Ci-2alkyl; and
each R6 is independently selected from the group consisting of H, Ci-2alkyl,
Ci-3alkyl-carbonyl-, and Ci-3alkoxy-carbonyl-.
23. The compound or salt according to any one of claims 1-21 , wherein B is phenyl or pyridinyl, optionally substituted by Ci-4alkyl, d^alkoxy, -C(0)NH2, -S02NH2, -C(0)OCH3, phenyl, pyridinyl, pyrrolidinyl, piperidinyl, morpholinyl, or -NRBaRBa,
-Ci-4alkylNR6R6, wherein each R6 is independently selected from the group consisting of H, Ci-2alkyl, and -C(0)CH3.
24. The compound or salt according to any one of claims 1-21 , wherein B is naphthyl, quinolyl, isoquinolyl, furo[3,2-c]pyridinyl, or 5,6,7,8-tetrahydroquinolyl.
25. The compound or salt according to any one of claims 1-16 and 22-24 having Formul
Figure imgf000062_0001
26. The compound or salt according to any one of claims 1-16 and 22-24 having Formula (lb)
Figure imgf000062_0002
wherein X is a bond, O or NR2.
27. The compound or salt according to any one of claims 1-8 and 22-24 having Formula (Ic):
Figure imgf000063_0001
wherein X is a bond, O or NR2.
28. The compound or salt according to any one of claims 1-2, 6-8 and 22-24 having Formula (Id):
Figure imgf000063_0002
wherein S, T, V, and U are each independently selected from the group consisting of N or CH.
29. The compound or salt according to claim 28, wherein two of S, T, V, and U are N and two are CH.
30. The compound or salt according to claim 28, wherein one of S, T, V, and U is N and three are CH.
31 . The compound according to claim 1 selected from the group consisting of any one of Examples 1 -1 1 , or a salt thereof.
32. A pharmaceutical composition comprising the compound or salt according to any one of claims 1 -31 and a pharmaceutically-acceptable excipient.
33. A method of inhibiting HDAC comprising contacting a cell with an effective amount of the compound or salt according to any one of claims 1-31.
34. A method of treating an HDAC-mediated disease or condition in a patient comprising administering to said patient a therapeutically-effective amount of the compound or salt according to any one of claims 1-31.
PCT/US2012/062510 2011-10-31 2012-10-30 Compounds and methods WO2013066835A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161553490P 2011-10-31 2011-10-31
US61/553,490 2011-10-31
US201261596404P 2012-02-08 2012-02-08
US61/596,404 2012-02-08

Publications (2)

Publication Number Publication Date
WO2013066835A2 true WO2013066835A2 (en) 2013-05-10
WO2013066835A3 WO2013066835A3 (en) 2015-05-21

Family

ID=48193010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/062510 WO2013066835A2 (en) 2011-10-31 2012-10-30 Compounds and methods

Country Status (1)

Country Link
WO (1) WO2013066835A2 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140142105A1 (en) * 2011-07-08 2014-05-22 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2016031815A1 (en) * 2014-08-26 2016-03-03 武田薬品工業株式会社 Heterocyclic compound
WO2017014170A1 (en) * 2015-07-17 2017-01-26 武田薬品工業株式会社 Heterocyclic compound
WO2017018804A1 (en) * 2015-07-27 2017-02-02 주식회사 종근당 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
KR20170013186A (en) 2015-07-27 2017-02-06 주식회사 종근당 1,3,4-Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR20170013836A (en) 2015-07-27 2017-02-07 주식회사 종근당 1,3,4-Oxadiazole Sulfonamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
WO2017023133A2 (en) 2015-08-04 2017-02-09 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017033946A1 (en) * 2015-08-25 2017-03-02 武田薬品工業株式会社 Heterocyclic compound
WO2017076742A1 (en) * 2015-11-05 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017103223A1 (en) * 2015-12-18 2017-06-22 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017157962A1 (en) 2016-03-15 2017-09-21 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017178549A1 (en) 2016-04-12 2017-10-19 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
CN108137517A (en) * 2015-10-02 2018-06-08 先正达参股股份有限公司 Kill microorganism oxadiazole derivatives
JP2018515489A (en) * 2015-05-07 2018-06-14 シーエイチディーアイ ファウンデーション，インコーポレーテッド Histone deacetylase inhibitors and compositions and methods of their use
WO2018202491A1 (en) * 2017-05-04 2018-11-08 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US20180370927A1 (en) * 2015-12-22 2018-12-27 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2019010192A1 (en) * 2017-07-05 2019-01-10 Fmc Corporation Fungicidal oxadiazoles
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019038042A1 (en) 2017-08-21 2019-02-28 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US10308643B2 (en) 2015-07-17 2019-06-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10492494B2 (en) 2015-11-13 2019-12-03 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10499644B2 (en) 2015-11-19 2019-12-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10640497B2 (en) 2015-12-02 2020-05-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10674727B2 (en) 2015-11-19 2020-06-09 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10687532B2 (en) 2015-11-13 2020-06-23 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10785980B2 (en) 2016-06-09 2020-09-29 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10798941B2 (en) 2016-01-08 2020-10-13 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2020240493A1 (en) 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10899724B2 (en) 2015-10-02 2021-01-26 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10986839B2 (en) 2016-04-11 2021-04-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US11083196B2 (en) 2016-03-24 2021-08-10 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
WO2021172887A1 (en) * 2020-02-25 2021-09-02 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US11192867B2 (en) 2016-06-03 2021-12-07 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2022038500A1 (en) 2020-08-18 2022-02-24 Pi Industries Limited Novel heterocyclic compounds for combating phytopathogenic fungi
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2022234470A1 (en) 2021-05-05 2022-11-10 Pi Industries Ltd. Novel fused heterocyclic compounds for combating phytopathogenic fungi
US11578066B1 (en) 2019-12-20 2023-02-14 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2023031775A1 (en) * 2021-08-31 2023-03-09 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating charcot-marie-tooth disease (cmt)
WO2023144737A1 (en) * 2022-01-28 2023-08-03 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating heart failure (hf)
WO2023223174A1 (en) * 2022-05-16 2023-11-23 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating idiopathic pulmonary fibrosis (ipf)
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
US11958845B2 (en) 2019-09-27 2024-04-16 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871753A (en) * 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
AU1730497A (en) * 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
MX2010006882A (en) * 2007-12-25 2010-10-05 Kissei Pharmaceutical Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition.
SG182401A1 (en) * 2010-01-13 2012-08-30 Tempero Pharmaceuticals Inc Compounds and methods

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520794A (en) * 2011-07-08 2014-08-25 ノバルティス アーゲー Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US20140142105A1 (en) * 2011-07-08 2014-05-22 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JPWO2016031815A1 (en) * 2014-08-26 2017-06-15 武田薬品工業株式会社 Heterocyclic compounds
WO2016031815A1 (en) * 2014-08-26 2016-03-03 武田薬品工業株式会社 Heterocyclic compound
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2018515489A (en) * 2015-05-07 2018-06-14 シーエイチディーアイ ファウンデーション，インコーポレーテッド Histone deacetylase inhibitors and compositions and methods of their use
WO2017014170A1 (en) * 2015-07-17 2017-01-26 武田薬品工業株式会社 Heterocyclic compound
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10308643B2 (en) 2015-07-17 2019-06-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10464911B2 (en) 2015-07-27 2019-11-05 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2018521110A (en) * 2015-07-27 2018-08-02 チョン クン ダン ファーマシューティカル コーポレーション 1,3,4-oxadiazolamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing them,
WO2017018804A1 (en) * 2015-07-27 2017-02-02 주식회사 종근당 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
RU2700696C2 (en) * 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-oxadisolamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof
KR20170013187A (en) 2015-07-27 2017-02-06 주식회사 종근당 1,3,4-Oxadiazole Amide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR20170013186A (en) 2015-07-27 2017-02-06 주식회사 종근당 1,3,4-Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
AU2016299485B2 (en) * 2015-07-27 2019-02-07 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
US10538498B2 (en) 2015-07-27 2020-01-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR101799005B1 (en) 2015-07-27 2017-11-17 주식회사 종근당 1,3,4-Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR101799009B1 (en) * 2015-07-27 2017-11-17 주식회사 종근당 1,3,4-Oxadiazole Amide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
US10584117B2 (en) 2015-07-27 2020-03-10 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
KR101799007B1 (en) 2015-07-27 2017-11-17 주식회사 종근당 1,3,4-Oxadiazole Sulfonamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
CN108026056B (en) * 2015-07-27 2021-08-03 株式会社钟根堂 1,3, 4-oxadiazole amide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions thereof
CN108026056A (en) * 2015-07-27 2018-05-11 株式会社钟根堂 As the 1,3,4- oxadiazole amide derivative compounds of 6 inhibitor of histone deacetylase and the pharmaceutical composition containing it
KR20170013836A (en) 2015-07-27 2017-02-07 주식회사 종근당 1,3,4-Oxadiazole Sulfonamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
RU2709207C2 (en) * 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-oxadiazole derivatives of compound as inhibitor of histone deacetylase 6 and pharmaceutical composition containing same
CN108137518B (en) * 2015-08-04 2021-08-31 株式会社钟根堂 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2017023133A3 (en) * 2015-08-04 2017-03-23 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2016303891B2 (en) * 2015-08-04 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR20170017792A (en) 2015-08-04 2017-02-15 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
JP2018523663A (en) * 2015-08-04 2018-08-23 チョン クン ダン ファーマシューティカル コーポレーション 1,3,4-oxadiazole derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same
CN108137518A (en) * 2015-08-04 2018-06-08 株式会社钟根堂 As 6 inhibitor of histone deacetylase 1,3,4- oxadiazole derivatives compound and include its pharmaceutical composition
WO2017023133A2 (en) 2015-08-04 2017-02-09 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR101799010B1 (en) * 2015-08-04 2017-11-17 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
US10717716B2 (en) 2015-08-04 2020-07-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017033946A1 (en) * 2015-08-25 2017-03-02 武田薬品工業株式会社 Heterocyclic compound
US10899724B2 (en) 2015-10-02 2021-01-26 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11180462B2 (en) 2015-10-02 2021-11-23 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10501425B2 (en) 2015-10-02 2019-12-10 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11066375B2 (en) 2015-10-02 2021-07-20 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN108137517A (en) * 2015-10-02 2018-06-08 先正达参股股份有限公司 Kill microorganism oxadiazole derivatives
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US20180317491A1 (en) * 2015-11-05 2018-11-08 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017076742A1 (en) * 2015-11-05 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN108347935A (en) * 2015-11-05 2018-07-31 巴斯夫欧洲公司 Qu Dai oxadiazole classes for preventing plant pathogenic fungi
US10555526B2 (en) 2015-11-05 2020-02-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10492494B2 (en) 2015-11-13 2019-12-03 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10687532B2 (en) 2015-11-13 2020-06-23 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10499644B2 (en) 2015-11-19 2019-12-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10674727B2 (en) 2015-11-19 2020-06-09 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10640497B2 (en) 2015-12-02 2020-05-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017103223A1 (en) * 2015-12-18 2017-06-22 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN108368098B (en) * 2015-12-18 2022-01-28 先正达参股股份有限公司 Microbicidal oxadiazole derivatives
CN108368098A (en) * 2015-12-18 2018-08-03 先正达参股股份有限公司 Kill microorganism oxadiazole derivatives
US20180370927A1 (en) * 2015-12-22 2018-12-27 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10798941B2 (en) 2016-01-08 2020-10-13 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11259524B2 (en) 2016-01-08 2022-03-01 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017157962A1 (en) 2016-03-15 2017-09-21 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11083196B2 (en) 2016-03-24 2021-08-10 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10986839B2 (en) 2016-04-11 2021-04-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017178549A1 (en) 2016-04-12 2017-10-19 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11192867B2 (en) 2016-06-03 2021-12-07 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10785980B2 (en) 2016-06-09 2020-09-29 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3475275A4 (en) * 2016-06-23 2020-01-22 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
WO2018202491A1 (en) * 2017-05-04 2018-11-08 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US11540518B2 (en) 2017-07-05 2023-01-03 Fmc Corporation Fungicidal oxadiazoles
WO2019010192A1 (en) * 2017-07-05 2019-01-10 Fmc Corporation Fungicidal oxadiazoles
US10435399B2 (en) 2017-07-31 2019-10-08 Takeda Pharmaceutical Company Limited HDAC6 inhibitory heterocyclic compound
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019038042A1 (en) 2017-08-21 2019-02-28 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
WO2020240493A1 (en) 2019-05-31 2020-12-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US11958845B2 (en) 2019-09-27 2024-04-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11926622B2 (en) 2019-12-20 2024-03-12 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11578066B1 (en) 2019-12-20 2023-02-14 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
KR102537615B1 (en) 2020-02-25 2023-05-30 주식회사 종근당 1,3,4-Oxadiazol Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR20210108555A (en) * 2020-02-25 2021-09-03 주식회사 종근당 1,3,4-Oxadiazol Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
WO2021172887A1 (en) * 2020-02-25 2021-09-02 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2022038500A1 (en) 2020-08-18 2022-02-24 Pi Industries Limited Novel heterocyclic compounds for combating phytopathogenic fungi
WO2022234470A1 (en) 2021-05-05 2022-11-10 Pi Industries Ltd. Novel fused heterocyclic compounds for combating phytopathogenic fungi
WO2023031775A1 (en) * 2021-08-31 2023-03-09 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating charcot-marie-tooth disease (cmt)
WO2023144737A1 (en) * 2022-01-28 2023-08-03 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating heart failure (hf)
WO2023223174A1 (en) * 2022-05-16 2023-11-23 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating idiopathic pulmonary fibrosis (ipf)

Also Published As

Publication number Publication date
WO2013066835A3 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
WO2013066835A2 (en) Compounds and methods
WO2013066839A2 (en) Compounds and methods
WO2013066838A1 (en) Compounds and methods
CN112638917B (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof
WO2013006408A1 (en) Compounds and methods
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
US8981084B2 (en) Oxadiazole HDAC inhibitors
WO2013066831A1 (en) Compounds and methods
AU2011205283B2 (en) Compounds and methods
WO2013066833A1 (en) Compounds and methods to inhibit histone deacetylase (hdac) enzymes
JP7373992B2 (en) Substituted pyrazole compounds and methods of their use for the treatment of hyperproliferative diseases
AU2018202568A1 (en) Heterocyclyl compounds as MEK inhibitors
WO2011088187A1 (en) Compounds and methods
ES2654332T3 (en) New azaheterocyclic compounds
WO2020012339A1 (en) Chemical compounds
CN103124730A (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
TWI762743B (en) Sulfonamide compounds and use thereof
US10947225B2 (en) Phosphotidylinositol 3-kinase inhibitors
KR20140117651A (en) Isoquinoline and naphthyridine derivatives
CA2901155A1 (en) Camkii inhibitors and uses thereof
KR20140070616A (en) Morpholino substituted urea or carbamate derivatives as mtor inhibitors
CN101663276A (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2013066836A1 (en) Compounds and methods
WO2013066834A1 (en) Compounds and methods
CA3181351A1 (en) Nampt modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12846702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 2905 DATED 07-08-14)

122 Ep: pct app. not ent. europ. phase

Ref document number: 12846702

Country of ref document: EP

Kind code of ref document: A2